var title_f30_9_30864="Dx WD neurological disorder";
var content_f30_9_30864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Approach to diagnosis of Wilson disease (WD) in a patient with a neurological disorder or psychiatric disease with or without liver disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 503px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Molecular testing means confirming homozygosity for one mutation or defining two mutations constituting compound heterozygosity.",
"    <br>",
"     Conversion to SI units: CPN &lt;20 mg/dL or 0.2 g/L; 24-hour urinary Cu &gt;40 micrograms/day or 0.6 micromol/day.",
"     <div class=\"footnotes\">",
"      CPN: ceruloplasmin; KF: Kayser-Fleischer.",
"     </div>",
"     <div class=\"reference\">",
"      Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47:2089.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30864=[""].join("\n");
var outline_f30_9_30864=null;
var title_f30_9_30865="ERCP (endoscopic retrograde cholangiopancreatography)";
var content_f30_9_30865=[" <h1 id=\"patTopicTitle\">",
"  Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/9/30865/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30865/contributors\" id=\"au4490\">",
"       Silvano Loperfido, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/9/30865/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30865/contributors\" id=\"se3699\">",
"       Douglas A Howell, MD, FASGE, FACG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/9/30865/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30865/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/9/30865?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ERCP OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Endoscopy is the examination of an internal body part with an instrument called an endoscope. Endoscopic retrograde cholangiopancreatography (ERCP) is a technique that uses x-ray to view the patient's bile and pancreatic ducts (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"mobipreview.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The function of the common bile duct and the pancreatic duct is to drain the gallbladder, liver, and pancreas; the two main ducts convey the bile and the pancreatic juice into the duodenum (the first part of the small intestine) (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"mobipreview.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ). The most common reason why someone would need an ERCP is because of a blockage of one of these ducts (often due to gallstones).",
"    </p>",
"    <p>",
"     The endoscopist (a doctor who has special training in the use of endoscopes) will examine the bile",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     pancreatic ducts, looking for abnormalities such as blockages, irregularity in the tissue, problems with the flow of bile or pancreatic fluid, stones, or tumors. If a problem is found, the endoscopist can often perform a procedure to repair or improve the condition; as a result, ERCP has replaced surgery in most patients with common bile duct and pancreatic disease.",
"    </p>",
"    <p>",
"     Many patients who need ERCP are hospitalized, but ERCP can also be performed as an outpatient procedure, depending on the patient's condition and on the complexity of the required procedure.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ERCP PREPARATION",
"     </span>",
"    </p>",
"    <p>",
"     You will be asked not to eat or drink anything for six to eight hours before the test. It is important for the stomach to be empty to allow the endoscopist to visualize the entire area, and to decrease the chance of vomiting during the procedure.",
"    </p>",
"    <p>",
"     You may be instructed to adjust the dose of your medications or stop taking specific medications prior to the examination. Some medications need to be discontinued for several days.",
"     <strong>",
"      All",
"     </strong>",
"     medications and dietary supplements should be discussed with your provider, since some are more important than others; for example, if you are taking a blood thinning medication, the provider will determine how and when you should stop taking this prior to ERCP.",
"    </p>",
"    <p>",
"     You will need a friend or family member to escort you home after the examination. This is because the medications used for sedation can impair reflexes, judgment, and your ability to drive (similar to the effects of alcohol).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      WHAT TO EXPECT IN THE ENDOSCOPY UNIT",
"     </span>",
"    </p>",
"    <p>",
"     Prior to the endoscopy, you will be asked some questions about your medical history and the medications you are currently taking; the ERCP procedure will also be explained in detail.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Sedation",
"     </span>",
"     &nbsp;&mdash;&nbsp;The nurse will start an intravenous (IV) line (by inserting a needle into a vein in the hand or arm) to administer medications. Most endoscopy units use a combination of a sedative to induce relaxation, and a medication to prevent discomfort. This is called \"conscious sedation\" because you are awake but the body is relaxed and pain is numbed. In some more complicated cases, you may be sedated more heavily or given anesthesia (put to sleep) for the ERCP.",
"    </p>",
"    <p>",
"     For safety reasons, you will be asked to remove eyeglasses or contact lenses, and dentures. Before the procedure begins, you may be given local anesthetic (a numbing spray applied onto the throat or gargled).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ERCP PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     ERCP is performed in a room that contains x-ray equipment. You will lie on a special table during the examination, generally on your left side or stomach.",
"    </p>",
"    <p>",
"     Although many people worry about discomfort from the endoscopy, most people tolerate it well and feel fine afterwards. Medications will be given through the IV line during the procedure. A plastic mouth guard is placed between the teeth to prevent damage to the teeth and endoscope. Many patients sleep during the test; others are very relaxed and not aware of the examination.",
"    </p>",
"    <p>",
"     The ERCP endoscope is a special flexible tube, approximately the size of a finger. It contains a lens and a light source that allows the endoscopist to view the inside of the patient's body; images are magnified on a monitor so that even very small details and changes can be seen. The endoscope also contains channels that allow the endoscopist to take biopsies (painless tissue samples) and introduce or withdraw fluid, air, or other instruments.",
"    </p>",
"    <p>",
"     You will be asked to swallow the tube; most people have no difficulty with this as a result of the sedating medications. Once the scope is inserted through the mouth, air is gently introduced to open up the esophagus, stomach, and intestine so the scope can be passed through those structures and to allow the endoscopist to see (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"mobipreview.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Depending on what the endoscopist sees during the ERCP, he or she may perform a variety of procedures or treatments.",
"    </p>",
"    <p>",
"     You may experience mild discomfort as air is introduced through the endoscope. This is not harmful and belching may relieve the sensation. The endoscope does not interfere with breathing. Taking slow and deep breaths during the procedure may help you to relax.",
"    </p>",
"    <p>",
"     The length of the examination varies, between 30 minutes and two hours (usually about an hour).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      RECOVERY AFTER ERCP",
"     </span>",
"    </p>",
"    <p>",
"     After ERCP, you will be monitored while the sedative medication wears off. The medicines cause most people to temporarily feel tired or have difficulty concentrating, so it is usually advised not to return to work or drive that day.",
"    </p>",
"    <p>",
"     The most common discomfort after the examination is a feeling of bloating as a result of the air introduced during the examination. This usually resolves quickly. Some people also have a mild sore throat. Most people are able to drink clear liquids shortly after the examination. In some cases, blood tests may be done the same day following ERCP.",
"    </p>",
"    <p>",
"     The endoscopist can usually tell the patient the results of their examination right away. If biopsies were taken, the tissue will need to be sent to a lab for analysis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ERCP COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     ERCP is a safe procedure and serious complications are uncommon. If complications do occur, they are usually mild, and may include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pancreatitis (inflammation of the pancreas) is the most frequent complication, occurring in about 3 to 5 percent of people undergoing ERCP. When it occurs, it is usually mild, causing abdominal pain and nausea, which resolve after a few days in the hospital. Rarely pancreatitis may be more severe. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/36/41537?source=see_link\">",
"        \"Patient information: Acute pancreatitis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Sometimes the endoscopist needs to make a cut into the ampulla (the place where the common bile duct and pancreatic duct join the small bowel) (",
"       <a class=\"graphic graphic_picture graphicRef63728 \" href=\"mobipreview.htm?23/44/24257\">",
"        picture 1",
"       </a>",
"       ). Bleeding can occur from a cut into the ampulla, but it is usually minimal and stops quickly by itself or can be controlled during the ERCP procedure.",
"      </li>",
"      <li>",
"       The ERCP scope or other instruments can cause a tear or hole in the intestine being examined (called perforation). This is a serious condition, often requiring surgical intervention, although it occurs rarely.",
"      </li>",
"      <li>",
"       Infection of the bile ducts (cholangitis) is rare in general, but it can occur, particularly in patients with certain preexisting conditions. Treatment of infections requires antibiotics and drainage of excess fluid.",
"      </li>",
"      <li>",
"       Aspiration (inhalation) of food or fluids into the lungs. The risk of this complication is minimal in people who do not eat or drink for several hours before the examination.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The following symptoms should be reported immediately:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Severe abdominal pain (not just gas cramps)",
"      </li>",
"      <li>",
"       A firm, distended abdomen",
"      </li>",
"      <li>",
"       Vomiting",
"      </li>",
"      <li>",
"       Fever or chills",
"      </li>",
"      <li>",
"       Difficulty in swallowing or a severe sore throat",
"      </li>",
"      <li>",
"       A crunching feeling under the skin",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H111834581\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18219859\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/56/1923?source=see_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/17/34066?source=see_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/26/42401?source=see_link\">",
"      Patient information: Pancreatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=see_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18219896\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/36/41537?source=see_link\">",
"      Patient information: Acute pancreatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H111834595\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=see_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/19/37175?source=see_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22905?source=see_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4822?source=see_link\">",
"      ERCP in children: Technique, success and complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/49/39705?source=see_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26216?source=see_link\">",
"      Post-ERCP bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/63/28666?source=see_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/38/20072?source=see_link\">",
"      Post-ERCP perforation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/25/23959?source=see_link\">",
"      Post-ERCP septic complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7882?source=see_link\">",
"      Rare complications of ERCP",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Gastrointestinal Endoscopy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.askasge.org/\">",
"      www.askasge.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Digestive Disease Information Clearinghouse",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/ercp/index.htm\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/ercp/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/9/30865/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/9/30865?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30865/abstract/1\">",
"      Cohen S, Bacon BR, Berlin JA, et al. National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc 2002; 56:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30865/abstract/2\">",
"      Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc 2005; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30865/abstract/3\">",
"      Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102:1781.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_9_30865=[""].join("\n");
var outline_f30_9_30865=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ERCP OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ERCP PREPARATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           WHAT TO EXPECT IN THE ENDOSCOPY UNIT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ERCP PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           RECOVERY AFTER ERCP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ERCP COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/2/12325\" title=\"figure 1\">",
"           Pancreas anatomy",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/44/24257\" title=\"picture 1\">",
"           Endoscopic view of the papilla of Vater",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_9_30866="Zones of the prostate gland";
var content_f30_9_30866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Zones of the prostate gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bulk of the prostate gland is contained within the peripheral zone. The transition zone is the site of benign prostatic hypertrophy. The majority of prostate cancers originate in the peripheral zone, whereas only 5 and 10 percent originate from the central and transition zones, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30866=[""].join("\n");
var outline_f30_9_30866=null;
var title_f30_9_30867="Parasternal long axis echo aortic valve vegetation";
var content_f30_9_30867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/52651/laxavend_conv.mp4?title=Parasternal+long+axis+echo+aortic+valve+vegetation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal long axis echocardiogram showing an aortic valve vegetation in a patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 257px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view from a 2-D echocardiogram of aortic valve endocarditis. Large vegetations can be seen on the ventricular surface of both aortic valve leaflets. The left ventricle is dilated, suggesting the presence of significant aortic regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30867=[""].join("\n");
var outline_f30_9_30867=null;
var title_f30_9_30868="X-ray insufficiency fracture of the sacrum";
var content_f30_9_30868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-ray insufficiency fracture of the sacrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the pelvis is from a 95-year-old male who sustained minimal trauma and complained of left groin pain. A fracture of the sacrum is not clearly visible on the first image (A) and perhaps a little more prominent on the magnified view (B) and best seen when highlighted and magnified on image C (red arrow). Fractures of the left sided superior and inferior pubic rami are also present (green arrows). These findings are consistent with insufficiency fractures of the left sacral ala and pubic ramus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gregory Waryasz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30868=[""].join("\n");
var outline_f30_9_30868=null;
var title_f30_9_30869="Cutaneous bacillary angiomatosis above eyebrow";
var content_f30_9_30869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous lesion of bacillary angiomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30869=[""].join("\n");
var outline_f30_9_30869=null;
var title_f30_9_30870="Dissection bladder off uterus";
var content_f30_9_30870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Sharp dissection of the bladder from the lower uterine segment during hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30870=[""].join("\n");
var outline_f30_9_30870=null;
var title_f30_9_30871="Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs";
var content_f30_9_30871=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     John Lauriello, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Austin R Campbell, PharmD, BCPP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30871/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/9/30871/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H19548548\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unpleasant adverse effects of antipsychotic drugs combined with patients&rsquo; disbelief of having an illness, which is common among individuals with schizophrenia, result in high rates of non-adherence to antipsychotics in the treatment of schizophrenia.",
"   </p>",
"   <p>",
"    Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who relapse due to non-adherence to antipsychotic medication. Rather than the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two to four week intervals.",
"   </p>",
"   <p>",
"    This topic addresses the use of LAI antipsychotics in the treatment of schizophrenia. The pharmacology, administration, comparative side effects and treatment of schizophrenia with standard (non-LAI) antipsychotics are discussed separately as is the management of antipsychotic side effects. The epidemiology, clinical manifestations, and diagnosis of schizophrenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20057?source=see_link\">",
"     \"Schizophrenia: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110448620\">",
"    <span class=\"h1\">",
"     LONG-ACTING INJECTABLE ANTIPSYCHOTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five long-acting injectable antipsychotics are currently available in the United States (US). Naming conventions vary among agents. As listed below, this topic uses the format: medication name followed by &ldquo;LAI.&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       Fluphenazine",
"      </a>",
"      decanoate (fluphenazine-LAI)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      decanoate (haloperidol-LAI)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      microspheres (risperidone-LAI)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"       Paliperidone",
"      </a>",
"      palmitate (paliperidone-LAI)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      pamoate (olanzapine-LAI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-acting injectable antipsychotics commonly used outside the US include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flupenthixol decanoate",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/19/10551?source=see_link\">",
"       Zuclopenthixol",
"      </a>",
"      decanoate",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/44/36550?source=see_link\">",
"       Pipotiazine",
"      </a>",
"      palmitate",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H495975\">",
"    <span class=\"h1\">",
"     ANTIPSYCHOTIC NON-ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment with antipsychotic medication is effective in reducing the rate of relapse in schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/1\">",
"     1",
"    </a>",
"    ]. However, patients taking oral antipsychotics for schizophrenia have an estimated adherence rate of less than 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. For a significant subset, non-adherence leads to relapse and hospitalization, which in some cases can be repeated and frequent.",
"   </p>",
"   <p>",
"    Factors contributing to medication non-adherence among individuals with schizophrenia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients with the disorder do not believe they have an illness and therefore reject treatment. This is particularly likely in patients early in their course of illness.",
"     </li>",
"     <li>",
"      Antipsychotic drugs can cause immediate unpleasant side effects, neurological consequences, metabolic changes, and the potential for long-term movement disorders",
"     </li>",
"     <li>",
"      Some patients treated with antipsychotic drugs experience residual hallucinations or delusions that &ldquo;convince&rdquo; them to stop the medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H495788\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for long-acting injectable (LAI) antipsychotics is for patients with schizophrenia who have a history of good response to an oral antipsychotic but who adhered poorly to the medication, leading to relapse. The efficacy of LAI antipsychotics on relapse in schizophrenia is discussed below. (See",
"    <a class=\"local\" href=\"#H19548576\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    LAI antipsychotics may be indicated for schizophrenia under other circumstances, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who, after stopping antipsychotics, become symptomatic with behaviors leading to highly adverse consequences (eg, arrests, assaults, self harm, loss of employment or housing). In addition to a possible effect on relapse, use of an LAI antipsychotic in these cases can provide early identification of non-adherence, ie, a missed visit for LAI antipsychotic administration.",
"     </li>",
"     <li>",
"      Patients with schizophrenia whose illness may be considered treatment-resistant except for a question of medication non-adherence. If the patient then responds to an LAI antipsychotic trial, then the prior lack of response to an oral antipsychotic may have been due to non-adherence. Alternatively, it may be that the oral ingestion process somehow did not build a high enough blood and subsequent brain drug level.",
"     </li>",
"     <li>",
"      Patients who respond well to a specific oral antipsychotic medication, but have a side effect that is dose dependent (eg, EPS or sexual dysfunction). These patients may benefit from the consistent blood level without higher daily peaks provided by the corresponding LAI antipsychotic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H495796\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to LAI antipsychotics include hypersensitivity to the medications or formulations.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    -LAI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    -LAI are contraindicated in severe central nervous system depression and coma. Unique contraindications include Parkinson&rsquo;s disease for haloperidol-LAI and subcortical brain damage, blood dyscrasias, and hepatic disease for fluphenazine-LAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H496039\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the available long-acting injectable (LAI) antipsychotics has an individual chemical makeup that is essentially that of the parent oral compound. The first-generation antipsychotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    -LAI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    -LAI, are potent dopamine blockers with less receptor activity for other neurotransmitters. The three second-generation antipsychotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    -LAI,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    -LAI, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    -LAI, rely on a blockade of both dopamine and serotonin receptors.",
"   </p>",
"   <p>",
"    The form of pharmacologic delivery of the LAI antipsychotics determines the immediacy of release, the sites of injection, and the potential interval between doses. The delivery system varies among the drugs. A method effective for one compound has not necessarily been applicable to the next. The first-generation LAI antipsychotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    -LAI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    -LAI, both utilize an ester form of the oral compound attached to a fatty acid (decanoic acid) chain. Once esterified, they are dissolved in an oil. Upon injection, the ester slowly disassociates from the oil allowing a gradual release of the medication over time.",
"   </p>",
"   <p>",
"    The second-generation LAI antipsychotics have required other means of delivery.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    -LAI utilizes a microsphere technology. The active compound, risperidone, is embedded into microspheres made of a polymer that degrades similarly to dissolvable suture.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     Paliperidone",
"    </a>",
"    -LAI is the long-acting formulation of paliperidone, a metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    . Paliperidone utilizes a crystal salt of paliperidone and the palmitate. Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    -LAI is a crystal salt of olanzapine pamoate and pamoic acid. Both paliperidone-LAI and olanzapine-LAI are suspended in water and injected. Once injected, the carrier salts slowly dissolve, releasing active medication. An advantage of paliperidone-LAI and olanzapine-LAI is the more immediate release of medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19548569\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with oral antipsychotics, dosing of the long-acting injectable (LAI) antipsychotics is optimized when clinical effectiveness is achieved while minimizing size effects. A table summarizes the delivery system, injection interval, and dosages of each LAI antipsychotic drug (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"mobipreview.htm?9/36/9806\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The first-generation antipsychotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    -LAI and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    -LAI, are administered via intramuscular injection in the deltoid or gluteal muscles. Due to their oil based nature and high viscosity, a Z-track injection technique is used to minimize leakage of the compound from the injection site (",
"    <a class=\"graphic graphic_figure graphicRef69880 \" href=\"mobipreview.htm?11/22/11622\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/6\">",
"     6",
"    </a>",
"    ]. Dosing of the first-generation LAI antipsychotics is based on the patient&rsquo;s dose of oral medication. Dose conversion formulations are given for each of the products discussed below. These formulations should be interpreted with caution in certain populations, i.e.",
"    <span class=\"nowrap\">",
"     poor/extensive",
"    </span>",
"    metabolizers and the elderly, since LAI do not undergo first pass metabolism which could possibly lead to variant concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25343020\">",
"    <span class=\"h2\">",
"     Fluphenazine-LAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing conversion from the oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    tablets to the LAI is approximately 1 mg oral administered daily to 1.25 mg LAI administered every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients should continue to supplement the LAI with oral medication for at least the first week after receiving the LAI due to its delay in achieving therapeutic plasma concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25343035\">",
"    <span class=\"h2\">",
"     Haloperidol-LAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    -LAI is 10 to 20 times the previous daily dose of oral haloperidol, given in four-week intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the initial haloperidol-LAI injection should not exceed 100 mg regardless of previous antipsychotic requirements in patients who are haloperidol-LAI naive. In cases where conversion requires administration of greater than 100 mg, the dose should be given in two separate injections, with 100 mg administered on day one and the remainder given in three to seven days.",
"    <br/>",
"    <br/>",
"    The usual maintenance dose is 10 to 15 times the previous daily dose of oral haloperidol given as a single injection. When haloperidol-LAI has been initiated using a loading strategy, maintenance dosing is typically started in the third month of therapy.",
"    <br/>",
"    <br/>",
"    Several loading-dose strategies have been evaluated for haloperidol-LAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Use of these techniques reduces the time required to achieve therapeutic plasma concentrations and eliminates the need for overlap with oral medication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A common strategy involves giving an initial injection of 20 times the oral daily dose. If the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      -LAI exceeds 100 mg then the dose should be administered as two separate injections. For large initial doses of haloperidol-LAI (ie, &ge; 400 mg) the total dose is sometimes given in a series of 3 injections (",
"      <a class=\"graphic graphic_table graphicRef59201 \" href=\"mobipreview.htm?9/36/9806\">",
"       table 1",
"      </a>",
"      ). Four weeks after initiation, the total dose is reduced by 25 percent and given as a single injection. The dose is again reduced by 25 percent of the original at the eight-week mark, and the patient is continued on this dose as maintenance.",
"     </li>",
"     <li>",
"      Another method is to initiate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      -LAI at the anticipated maintenance dose and supplement the patient with oral haloperidol. If this approach is taken, oral medication should be gradually tapered over a one month period. We typically reduce the dose by 25 percent at weekly intervals; however, some patients may require faster or slower tapering schedules depending on individual response. While this strategy increases the time necessary to achieve steady state concentrations, it offers the clinician more control over the total amount of haloperidol the patient receives each day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Second-generation LAI antipsychotics differ from first-generation drugs in aspects of administration and dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25343054\">",
"    <span class=\"h2\">",
"     Olanzapine-LAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    -LAI is based on the patient&rsquo;s dose of oral medication; however, the conversation ratio is dose dependent (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"mobipreview.htm?9/36/9806\">",
"     table 1",
"    </a>",
"    ). Supplementation of the initial LAI dose with oral olanzapine is not necessary. Olanzapine-LAI should only be administered via deep intramuscular gluteal injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/10\">",
"     10",
"    </a>",
"    ]. Due to the potential for a severe adverse reaction to olanzapine-LAI, patients must be observed for at least three hours after every injection. (See",
"    <a class=\"local\" href=\"#H249702865\">",
"     'Post-injection delirium sedation syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25343088\">",
"    <span class=\"h2\">",
"     Risperidone-LAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    -LAI is administered via deep intramuscular injection in the deltoid or gluteal muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/11\">",
"     11",
"    </a>",
"    ]. The medication is initiated at a dose of 25 mg every two weeks. For patients who do not respond to this dose, upward titration by 12.5 to 25 mg may be made at four week intervals to a maximum of 50 mg per injection. Oral risperidone should be continued at the full dose for three weeks after the first long-acting injection due to the formulation&rsquo;s delay in release of medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25343110\">",
"    <span class=\"h2\">",
"     Paliperidone-LAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    -LAI consists of a 234 mg injection in the deltoid muscle on day one followed by another deltoid injection of 156 mg one week later. This second injection may be administered four days before or after the weekly time point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/12\">",
"     12",
"    </a>",
"    ]. The recommended maintenance dose of 117 mg is begun four weeks after the second injection, and may be administered in either the deltoid or gluteal muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/13\">",
"     13",
"    </a>",
"    ]. No overlap with oral paliperidone is necessary after initiating paliperidone-LAI. Some patients may benefit from lower or higher maintenance doses of paliperidone-LAI; dosage recommendations range from 39 to 234 mg. Paliperidone is primarily excreted through the urine so dose adjustments are necessary in patients with mild renal dysfunction. If creatine clearance is 50 to 80",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    then paliperidone-LAI should be initiated at 156 mg on day one followed by 117 mg one week later. The monthly maintenance dose is 78 mg every four weeks. Paliperidone-LAI is not recommended in individuals with Cl",
"    <sub>",
"     cr",
"    </sub>",
"    &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19548576\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting",
"    injectable (LAI) formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/14\">",
"     14",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/15,16\">",
"     15,16",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/17-19\">",
"     17-19",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] have shown efficacy in schizophrenia compared to placebo in randomized trials. There are no known differences in efficacy among the LAI antipsychotics.",
"   </p>",
"   <p>",
"    Meta-analyses of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/14,24,25\">",
"     14,24,25",
"    </a>",
"    ] and individual trials of newer agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ] have generally not found LAI antipsychotics to improve medication adherence or reduce relapse rates in samples of patients with schizophrenia compared to oral antipsychotics. Critiques of these trials note that they tended to enroll compliant patients with stable schizophrenia, and without comorbid substance abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In so doing, LAIs have not been tested in the population for which they may be best suited, ie, patients with unstable schizophrenia and frequent relapse. Other methodologic limitations included inadequate blinding in some trials and that patients in both LAI and oral groups received staff support in randomized trials that did not reflect real world conditions.",
"   </p>",
"   <p>",
"    In a randomized trial that addressed some of these shortcomings, 369 patients with unstable schizophrenia or schizoaffective disorder were randomized to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    -LAI or to an oral antipsychotic and followed for up to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/28\">",
"     28",
"    </a>",
"    ]. Participants were limited to those hospitalized at the time of enrollment (40 percent), hospitalized within the last two years, or having increased their use of health services to prevent relapse and hospitalization. Study personnel who rated patients&rsquo; clinical status were blinded to their study-drug assignments. However, the trial found that, compared to patients receiving oral antipsychotics, patients receiving risperidone-LAI did not differ in their hospitalization rate (hazard ratio = 0.87, 95% CI: 0.63 to 1.20) or duration of adherence to treatment. Despite efforts to enroll patients for whom LAI antipsychotics were most indicated, the trial (by practical necessity) excluded patients with recent substance detoxification, unstable living arrangements, a history of assault or suicidal behavior requiring urgent intervention, or inability or unwillingness to consent to a treatment study. Other limitations were an underpowered sample size and possible bias of unblinded physicians who made decisions regarding hospitalization.",
"   </p>",
"   <p>",
"    In view of the limited ability of clinical trials to study patients for whom LAI antipsychotics may be most useful, and based on our clinical experience, we suggest the use of LAI antipsychotics for patients with schizophrenia who relapse due to medication non-adherence. We have found that LAI antipsychotics may help some patients break a cycle of multiple hospitalizations resulting from unstable illness, often compounded by chaotic social structure and substance use.",
"   </p>",
"   <p>",
"    Although not rigorously studied, LAI antipsychotics should be used in conjunction with cognitive and behavioral techniques that help patients understand their illness and need for treatment. Unfortunately, such concurrent treatment is not routinely available, leading to an overreliance on long-acting medication as sole treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19548590\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local injection site complications, such as pain or redness, have been observed in up to 10 percent of individuals receiving long-acting injectable (LAI) antipsychotics. At a comparable dose, the LAI antipsychotics have lower maximum blood levels and lesser dose-related side effects (including sedation, and hyperprolactinemia) compared to their oral counterparts, due to differences in pharmacokinetics. There is no advantage to LAIs compared to oral antipsychotics with side effects unrelated to dose and blood level (including tardive dyskinesia, and metabolic syndrome). Each LAI has the same US FDA warnings, precautions, and contraindications as its parent compound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H249702865\">",
"    <span class=\"h2\">",
"     Post-injection delirium sedation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    -LAI in clinical trials experienced a rare (less than one percent) but serious adverse event termed &ldquo;post-injection delirium sedation syndrome&rdquo; (PDSS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. PDSS is believed to be due to inadvertent intravascular injection of olanzapine-LAI, leading to an increased blood level of the agent. Symptoms resemble an overdose of oral olanzapine and include confusion, disorientation, anxiety, dizziness, excessive sedation, and extrapyramidal symptoms. The majority of patients experiencing these effects developed symptoms within the first hour after an injection. Due to the potential for PDSS, patients, providers, institutions, and pharmacies need to be registered and receive training before olanzapine-LAI can be dispensed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30871/abstract/10,31,32\">",
"     10,31,32",
"    </a>",
"    ]. Patients must be directly observed by a healthcare professional at the registered facility for at least three hours after every injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19548597\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance treatment with antipsychotic medication is effective in reducing relapse in schizophrenia. However, patients are frequently non-adherent to these drugs, leading to frequent relapse and hospitalization in a significant proportion. (See",
"    <a class=\"local\" href=\"#H495975\">",
"     'Antipsychotic non-adherence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating patients with schizophrenia who experience relapses due to non-adherence. Rather than the daily pill-taking required with oral formulations, LAI antipsychotics are administered by injection at two to four week intervals. (See",
"      <a class=\"local\" href=\"#H495788\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LAI formulations are available for the first-generation antipsychotics",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      , and the second-generation agents",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"       paliperidone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H110448620\">",
"       'Long-acting injectable antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dosing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      is based on the patient&rsquo;s dose of the oral formulation, while standardized dosing is used for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44728?source=see_link\">",
"       paliperidone",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef59201 \" href=\"mobipreview.htm?9/36/9806\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19548569\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As an example,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      -LAI is administered via deep intramuscular injection in the deltoid or gluteal muscles, initially at a dose of 25 mg every two weeks. For patients who do not respond to this dose, upward titration by 12.5 to 25 mg may be made at four week intervals to a maximum of 50 mg per injection. Oral risperidone should be continued for three weeks after the first long-acting injection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-acting injectable antipsychotics have shown efficacy in reducing symptoms of schizophrenia compared to placebo in randomized trials. (See",
"      <a class=\"local\" href=\"#H19548576\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of LAI antipsychotics for patients with schizophrenia who relapse due to medication non-adherence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19548576\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local injection site reactions, such as pain or redness, are the most common complication of LAI antipsychotic treatment. While many of these reactions are tolerable, more severe site reactions would merit termination of the LAI. (See",
"      <a class=\"local\" href=\"#H19548590\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A rare but serious adverse event has been seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      -LAI, post-injection delirium sedation syndrome, which presents with symptoms resembling antipsychotic overdose (including confusion, oversedation, dizziness, and extrapyramidal symptoms). Providers of this agent are required to receive training in its use and patients must be observed for three hours after each injection. (See",
"      <a class=\"local\" href=\"#H19548590\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/1\">",
"      Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985; 46:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/2\">",
"      Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/3\">",
"      Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998; 49:196.",
"     </a>",
"    </li>",
"    <li>",
"     Fluphenazine Decanoate [package insert]. Schaumburg, IL: APP Pharmaceuticals, LLC; 2009",
"    </li>",
"    <li>",
"     Haloperidol Decanoate [package insert]. Schaumburg, IL: APP Pharmaceuticals, LLC; 2008",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/6\">",
"      Belanger MC, Chouinard G. Technique for injecting long-acting neuroleptics. Br J Psychiatry 1982; 141:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/7\">",
"      Schooler NR, Levine J. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatr Neuropsychopharmakol 1976; 9:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/8\">",
"      Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984; 45:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/9\">",
"      Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985; 10:315.",
"     </a>",
"    </li>",
"    <li>",
"     Zyprexa Relprevv [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010",
"    </li>",
"    <li>",
"     Risperdal Consta [package insert]. Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2009",
"    </li>",
"    <li>",
"     Paliperidone palmitate. FDA approved product information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed February 14, 2013)",
"    </li>",
"    <li>",
"     Invega Sustenna [package insert]. Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/14\">",
"      David A, Adams CE, Eisenbruch M, et al. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev 2005; :CD000307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/15\">",
"      Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand 1980; 62:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/16\">",
"      Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/17\">",
"      Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/18\">",
"      Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/19\">",
"      Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/20\">",
"      Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010; 35:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/21\">",
"      Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev 2012; 6:CD008296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/22\">",
"      Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010; 116:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/23\">",
"      Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008; 69:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/24\">",
"      Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/25\">",
"      Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009; 52:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/26\">",
"      Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 2007; 68:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/27\">",
"      Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007; 191:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/28\">",
"      Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364:842.",
"     </a>",
"    </li>",
"    <li>",
"     McDonnell DP, Sorsaburu S, Brunner E, et.al. Injection-related adverse events observed with olanzapine long-acting injection. Poster presented at the Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum. July 13-17, 2008. Munich, Germany",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/30\">",
"      Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract 2009; 63:140.",
"     </a>",
"    </li>",
"    <li>",
"     Gulliver A, McDonnell DP, Sorsaburu S, et.al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol 2008; 11:152",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30871/abstract/32\">",
"      Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 2010; 10:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15250 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-FFF4911520-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30871=[""].join("\n");
var outline_f30_9_30871=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19548597\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548548\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110448620\">",
"      LONG-ACTING INJECTABLE ANTIPSYCHOTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H495975\">",
"      ANTIPSYCHOTIC NON-ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H495788\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H495796\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H496039\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548569\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25343020\">",
"      Fluphenazine-LAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25343035\">",
"      Haloperidol-LAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25343054\">",
"      Olanzapine-LAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25343088\">",
"      Risperidone-LAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25343110\">",
"      Paliperidone-LAI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548576\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548590\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H249702865\">",
"      Post-injection delirium sedation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19548597\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15250|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/22/11622\" title=\"figure 1\">",
"      Technique for Z-track injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/36/9806\" title=\"table 1\">",
"      Dose and admin of LAI antipsychotic for schizophrenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20057?source=related_link\">",
"      Schizophrenia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_9_30872="Assessment and management of scalp lacerations";
var content_f30_9_30872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of scalp lacerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Judd E Hollander, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Martin Camacho, MSN, ACNP-BC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30872/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/9/30872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4201456\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp lacerations are a common injury. Clinical evaluation should identify associated serious head injury, laceration of the galea, or bony defect of the skull. After hemostasis is achieved and the wound is irrigated, scalp lacerations are typically closed with surgical staples under local anesthesia. Sutures may be preferred over staples for large, gaping wounds and to provide hemostasis for wounds with brisk bleeding.",
"   </p>",
"   <p>",
"    The assessment and management of scalp lacerations will be reviewed here. Minor wound management, methods of suture placement, and closure of skin wounds with staples are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link\">",
"       \"Closure of skin wounds with sutures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link\">",
"       \"Closure of minor skin wounds with staples\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4198638\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in all trauma patients, the initial clinical assessment should provide rapid identification of potentially fatal conditions. Evaluation should rapidly identify airway compromise (while maintaining cervical spine immobilization), impaired breathing, hemorrhagic shock, and altered level of consciousness upon patient arrival at the emergency department. Such systematic evaluation helps ensure detection of potentially life-threatening injuries. The approach to the injured child or adult is discussed in detail separately (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H9#H9\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=see_link&amp;anchor=H1929690#H1929690\">",
"     \"Initial management of trauma in adults\", section on 'Primary evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scalp lacerations should be identified during a vigilant and organized secondary survey. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H27#H27\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Secondary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4198712\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should identify the following aspects of the injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic force (eg, high-speed motor vehicle collision with significant likelihood of associated injuries versus fall from standing height with no other symptoms)",
"     </li>",
"     <li>",
"      Associated symptoms of head injury (eg, altered mental status, vomiting, headache) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=see_link&amp;anchor=H18#H18\">",
"       \"Minor head trauma in infants and children\", section on 'History'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Wound age",
"     </li>",
"     <li>",
"      Likelihood of wound contamination (eg, clean laceration from table edge with low risk of contamination versus bite wound with high risk of bacterial contamination)",
"     </li>",
"     <li>",
"      Potential presence of foreign body (eg, fall on to glass or gravel)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history should also include a comprehensive review of past medical history (eg, diabetes mellitus, cancer, prior keloid formation), medication use (eg, immunosuppressive agents), and social habits (ie, alcohol or drug use) that may negatively affect healing and increase the risk for poor outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H8#H8\">",
"     \"Minor wound preparation and irrigation\", section on 'Risks for poor outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the clinician should also elicit allergies to any medications, especially local anesthetics, and the patient&rsquo;s tetanus immunization status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=see_link&amp;anchor=H19#H19\">",
"     \"Allergic reactions to local anesthetics\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/53/12122?source=see_link&amp;anchor=H22537779#H22537779\">",
"     \"Assessment and management of facial lacerations\", section on 'Tetanus prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4198847\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scalp should be examined carefully to evaluate for signs of injury to the underlying structures (",
"    <a class=\"graphic graphic_picture graphicRef87633 \" href=\"mobipreview.htm?41/58/42918\">",
"     picture 1",
"    </a>",
"    ). The layers of concern in the scalp include the subcutaneous tissue, galea aponeurosis, connective tissue and periosteum overlying the bone. Visible or palpably bony defects warrant computed tomography of the head to determine presence of intracranial injury or penetration of the wound through the skull.",
"   </p>",
"   <p>",
"    Removal of all foreign debris and blood will allow for proper assessment. Bleeding is a common problem with scalp lacerations. Hemostasis of a wound is necessary to allow for an appropriate examination. Direct pressure for approximately 15 minutes with or without local injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    with epinephrine can often provide sufficient hemostasis. If these methods fail, the clinician should evert the edges of the scalp wound using manual manipulation, hemostats, or skin hooks. The wound is then rapidly closed with sutures. In this situation, simple interrupted sutures provide circumferential wound closure and thus better control of bleeding than noncircumferential wound closure with staples. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"     \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following attributes of the wound should be noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Length of laceration in centimeters",
"     </li>",
"     <li>",
"      Depth of laceration (epidermis, dermis, subcutaneous fat, muscle, or bone)",
"     </li>",
"     <li>",
"      Shape of laceration (eg, linear, curvilinear, stellate, or corner)",
"     </li>",
"     <li>",
"      Presence of gross contamination or visible foreign bodies",
"     </li>",
"     <li>",
"      The presence of skin loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4198993\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with clinical findings (eg, laceration from broken glass, debris in the wound, visible or palpable bony defect) that suggest the presence of a foreign body or bony injury warrant appropriate imaging as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain radiographs can identify most radiopaque foreign bodies (eg, glass, metal, rocks) while ultrasound can often locate many nonradiopaque foreign bodies.",
"     </li>",
"     <li>",
"      Skull fractures and the potential associated intracranial injury are best evaluated by computed tomography of the head without contrast. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13704?source=see_link&amp;anchor=H15#H15\">",
"       \"Skull fractures in children\", section on 'Radiologic evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=see_link&amp;anchor=H6#H6\">",
"       \"Skull fractures in adults\", section on 'Diagnostic imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199042\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp wounds with significant skin loss that requires grafting or associated with penetration into the cranial vault warrant consultation with an appropriate surgical subspecialist (eg, plastic surgeon, neurosurgeon). Most other scalp lacerations do not require subspecialty consultation or referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199100\">",
"    <span class=\"h1\">",
"     WOUND REPAIR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199108\">",
"    <span class=\"h2\">",
"     Indications for primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary closure (ie, wound repair at the time of presentation) is usually the preferred treatment for scalp lacerations into or through the dermis. If these wounds are not closed, they will heal by secondary intention but have increased scarring and risk for wound infection. In general, a scalp laceration with no increased risk factors for infection can be closed up to 48 hours after injury if appropriate cleansing is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed primary closure (ie, cleansing and debridement at the time of initial presentation with definitive wound closure performed electively four to five days later) may be warranted for wounds that present after 24 hours and have increased risk for infection. There is no definite time point after which wounds must be closed by delayed primary closure. In general, the decision should be based upon the time from injury, patient factors that increase the risk of infection (ie, vascular insufficiency), and wound factors (contamination or foreign body potential). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the excellent blood flow to the scalp, wound infections are rare, even following repair of contaminated wounds or bite wounds. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link\">",
"     \"Initial management of animal and human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199115\">",
"    <span class=\"h2\">",
"     Contraindications and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. Scalp laceration closure should also not delay further evaluation and definitive care of more urgent traumatic injuries, including underlying intracranial injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When closure is delayed, saline-soaked gauze packing (wet-dry closure) can be provided to enhance secondary healing. Appropriate antibiotic coverage (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or, in penicillin allergic patients,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) aimed at the flora of the skin and possibly upper respiratory tract can be initiated in selected patients with wounds other than bite wounds (eg, patient with diabetes mellitus, or other risks for poor wound outcome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H10#H10\">",
"     \"Minor wound preparation and irrigation\", section on 'Type of closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications and empiric oral antibiotic regiments for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"mobipreview.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"mobipreview.htm?6/17/6429\">",
"     table 2",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199182\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for the care of scalp lacerations includes control of bleeding, provision of anesthesia and analgesia, wound debridement and cleansing, and assembly of appropriate equipment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemostasis",
"      </strong>",
"      &ndash; Bleeding may be profuse and substantial blood loss can occur with scalp lacerations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Direct pressure for approximately 15 minutes with or without local injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine can often provide sufficient hemostasis. If these methods fail, the edges of the scalp wound can be everted manually or using hemostats or skin hooks and the wound rapidly closed with sutures. In this situation, sutures provide circumferential wound closure and thus better control of bleeding than noncircumferential wound closure with staples.",
"     </li>",
"     <li>",
"      <strong>",
"       Anesthesia",
"      </strong>",
"      &ndash; In children and apprehensive older patients, topical anesthesia with LET (4 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , 0.1 percent epinephrine, 0.5 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/12/36032?source=see_link\">",
"       tetracaine",
"      </a>",
"      ) available as an aqueous solution or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"       methylcellulose",
"      </a>",
"      &nbsp;based gel either alone or prior to infiltration of local anesthesia facilitates repair for small (&lt;4 cm) lacerations, especially when combined with concurrent nonpharmacologic interventions that use biobehavioral and cognitive distraction techniques. The wound should be assessed for analgesia, and if incomplete, infiltration with buffered lidocaine without epinephrine should be performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link&amp;anchor=H2#H2\">",
"       \"Topical anesthetics in children\", section on 'LET'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link&amp;anchor=H1684879#H1684879\">",
"       \"Procedural sedation in children outside of the operating room\", section on 'Nonpharmacologic interventions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Alternatively, infiltration of buffered lidocaine with epinephrine provides adequate analgesia and vasoconstriction to limit bleeding with an acceptable pain of injection for most patients (",
"      <a class=\"graphic graphic_table graphicRef56799 \" href=\"mobipreview.htm?25/56/26509\">",
"       table 3",
"      </a>",
"      ). Lidocaine with epinephrine (1:100,000-1:200,000) should be used with caution for large scalp tissue flaps [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. Plain lidocaine (1 or 2 percent),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"       mepivacaine",
"      </a>",
"      , or very dilute lidocaine with epinephrine (1:400,000-1:800,000) should be used instead [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link&amp;anchor=H2#H2\">",
"       \"Infiltration of local anesthetics\", section on 'Lidocaine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link&amp;anchor=H540550#H540550\">",
"       \"Infiltration of local anesthetics\", section on 'Methods to decrease injection pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Wound debridement and cleansing",
"      </strong>",
"      &ndash; Local or regional anesthesia prior to initiating irrigation and wound cleansing improves patient comfort. In young children and patients with heavily contaminated wounds, procedural sedation may also be necessary so that wound preparation can be tolerated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=see_link\">",
"       \"Procedural sedation in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Hair trimming is often necessary to appreciate the extent of the wound and determine if full thickness skin lacerations are present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/8\">",
"       8",
"      </a>",
"      ]. Hair shaving should be avoided as it may increase debris in the wound. Hair can also be patted down with petrolatum, water, or povidone-iodine ointment to allow for visualization of the wound.",
"      <br/>",
"      <br/>",
"      The volume of wound irrigation for scalp lacerations is based upon wound size and degree of contamination. Moderate sized scalp lacerations (&gt;2.5 to 5.0 cm in length) with minimal contamination may be irrigated with 100 to 150 mL while contaminated wounds and wounds &gt;5.0 cm in length may benefit from irrigation with 200 mL or more. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H20#H20\">",
"       \"Minor wound preparation and irrigation\", section on 'Volume'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, scalp lacerations can be irrigated with isotonic 0.9 percent normal saline. For clean wounds, running tap water can be an acceptable alternative in regions where the local water supply is sanitary. Larger, more extensive laceration (animal or human bites, contaminated wounds) can be irrigated with a mixture of 1:10",
"      <span class=\"nowrap\">",
"       povidone/iodine",
"      </span>",
"      solution (Betadine&reg; solution) and isotonic 0.9 percent normal saline. (See",
"      <span class=\"nowrap\">",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H18#H18\">",
"        \"Minor wound preparation and irrigation\", section on 'Irrigation solution'",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Povidone/iodine",
"      </span>",
"      surgical scrub (Betadine&reg; surgical scrub) should",
"      <strong>",
"       not",
"      </strong>",
"      be used because it contains ionic detergent that may be toxic to wound tissue. The clinician should also",
"      <strong>",
"       avoid",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      solution due to its potential for dermatologic irritation and hair bleaching qualities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H18#H18\">",
"       \"Minor wound preparation and irrigation\", section on 'Irrigation solution'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Wound debridement and irrigation is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H14#H14\">",
"       \"Minor wound preparation and irrigation\", section on 'Debridement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link&amp;anchor=H17#H17\">",
"       \"Minor wound preparation and irrigation\", section on 'Irrigation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199657\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following equipment should be assembled for scalp laceration repair: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sterile gloves",
"     </li>",
"     <li>",
"      Surgical mask",
"     </li>",
"     <li>",
"      Eye protection",
"     </li>",
"     <li>",
"      Buffered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine 1 percent or similar local anesthetic",
"     </li>",
"     <li>",
"      Small volume syringe (eg, 3 or 6 mL) with small gauge needle (eg, 27 or 30 gauge) for infiltration of local anesthetic",
"     </li>",
"     <li>",
"      Suture material (",
"      <a class=\"graphic graphic_table graphicRef52335 \" href=\"mobipreview.htm?5/33/5662\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Needle holder",
"     </li>",
"     <li>",
"      Hemostat",
"     </li>",
"     <li>",
"      Scalpel with handle (#10 or 15 blade)",
"     </li>",
"     <li>",
"      Tissue forceps",
"     </li>",
"     <li>",
"      Scissors",
"     </li>",
"     <li>",
"      Surgical probe",
"     </li>",
"     <li>",
"      Sterile 4 x 4 gauze",
"     </li>",
"     <li>",
"      Absorbent towels",
"     </li>",
"     <li>",
"      Sterile field drapes",
"     </li>",
"     <li>",
"      Stapler, dermal adhesive (for hair apposition technique), or sutures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emergency departments generally are well equipped with minor surgical or suture trays that contain the instruments, sterile gauze, towels, and drapes listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199680\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the closure of scalp wounds include stapling, modified hair apposition, and sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199768\">",
"    <span class=\"h2\">",
"     Surgical staples",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that scalp lacerations through the dermis undergo skin closure with surgical staples rather than sutures (",
"    <a class=\"graphic graphic_figure graphicRef69979 \" href=\"mobipreview.htm?6/5/6226\">",
"     figure 2",
"    </a>",
"    ). However, sutures are an acceptable option if surgical staples are not available in a timely manner and are preferred to promote hemostasis when brisk bleeding is present.",
"   </p>",
"   <p>",
"    The benefits of staples relative to sutures include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid closure of wound edges",
"     </li>",
"     <li>",
"      Noncircumferential wound closure that avoids potential tissue strangulation, although this concern is much less important in the highly vascular scalp",
"     </li>",
"     <li>",
"      No cross hatch marks, although these are primarily seen in sutured wounds when suture removal is delayed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies also suggest that staple closure is faster and less expensive for closure of skin wounds with similar cosmetic results and no added wound complications when compared to suturing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. Of these, the following studies limited their evaluation to scalp wounds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 88 children with scalp lacerations found that closure with staples was six times faster than closure with nylon sutures (65 versus 397 seconds, p&lt;0.0001) and was significantly less expensive when considering the cost of equipment and physician time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/12\">",
"       12",
"      </a>",
"      ]. No cosmetic or infectious complications were noted in either group at a one week follow-up that was completed by 91 percent of patients.",
"     </li>",
"     <li>",
"      A randomized trial of 200 adults with scalp lacerations showed that the mean time to close a scalp wound with staples was significantly less than with sutures (49 versus 380 seconds) with no difference in wound complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A trial of 31 children with scalp wounds demonstrated that cosmetic outcomes at 6 to 18 months were similar between wounds closed by staples or sutures as measured by a visual analogue scale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/16\">",
"       16",
"      </a>",
"      ]. Time for wound closure was significantly shorter with staples when compared to sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Human studies of wound closure have not documented a lower wound infection rate in scalp wounds closed with staples. However, animal studies have shown that skin wounds closed by staples are more resistant to infection than skin wounds closed with monofilament nylon suture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a quick method, stapling is painful. Thus, we advise that most patients receive local anesthesia prior to skin closure with staples. (See",
"    <a class=\"local\" href=\"#H4199182\">",
"     'Preparation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Closure of minor skin wounds with staples is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4199775\">",
"    <span class=\"h2\">",
"     Modified hair apposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modified hair apposition (",
"    <a class=\"graphic graphic_figure graphicRef63626 \" href=\"mobipreview.htm?25/50/26403\">",
"     figure 3",
"    </a>",
"    ) is another technique that may be used instead of staples or sutures to close scalp lacerations. This approach is appropriate for wounds that are straight and less than 10 cm. Patients need to have hair that is longer than 1 cm and scalp bleeding must be controlled prior to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. We prefer the modified hair apposition technique over hair tying because it can be performed in patients with hair as short as 1 cm. Scalp wound closure with staples may be faster than the modified hair apposition technique with similar wound outcomes, and closure with sutures is preferred when control of bleeding is necessary.",
"   </p>",
"   <p>",
"    Modified hair apposition is performed in the following manner (",
"    <a class=\"graphic graphic_figure graphicRef63626 \" href=\"mobipreview.htm?25/50/26403\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ensure that the wound is clean and is not actively bleeding.",
"     </li>",
"     <li>",
"      Using forceps or hemostats, grasp between 5 and 15 strands of hair directly opposite and on each side of the wound.",
"     </li>",
"     <li>",
"      Cross the strands once without knotting until the wound edges are apposed.",
"     </li>",
"     <li>",
"      Maintain the strand closure by having an assistant place one drop of glue where the strands cross.",
"     </li>",
"     <li>",
"      Avoid getting glue into the wound. If glue is introduced into the wound during hair apposition, wide scarring with a bald spot can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should not let the wound get wet for 48 hours after repair and should be informed that the glue will come out with time.",
"   </p>",
"   <p>",
"    Limited evidence suggests that modified hair apposition may permit faster scalp wound closure with fewer complications than sutures. For example, in a randomized study of 189 patients with scalp lacerations, wound healing after modified hair apposition was similar to sutured wounds with a significantly lower risk for complications (eg, infection, scarring, bleeding, or wound breakdown [7 versus 22 percent]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/20\">",
"     20",
"    </a>",
"    ]. Hair apposition was less painful and quicker than wound closure with sutures (median closure time 5 versus 15 minutes). However, the complication rate for sutures in this study was higher than reported in other scalp wound studies, thus limiting the generalizability of these results.",
"   </p>",
"   <p>",
"    Modified hair apposition is obviously not a suitable technique for bald patients or those with short hair (&lt;1 cm). Profusely bleeding scalp wounds and those with gross contamination may require close clipping of hair to achieve hemostasis, proper wound cleansing, and debridement and also preclude the use of the hair apposition technique. In addition, the modified hair apposition technique requires an assistant to apply glue to the hair strands.",
"   </p>",
"   <p>",
"    Although modified hair apposition appears to have advantages when compared to suture placement in patients with the appropriate wound and hair characteristics, the benefits when compared to closure of scalp wounds with staples is less well studied. Modified hair apposition takes approximately 5 to 10 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/20\">",
"     20",
"    </a>",
"    ] to perform while staple closure typically takes approximately 1 minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, modified hair apposition avoids the need for staple removal which requires a special instrument and can be painful. Both methods provide good cosmetic results with few complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link&amp;anchor=H11#H11\">",
"     \"Closure of minor skin wounds with staples\", section on 'Staple removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200180\">",
"    <span class=\"h2\">",
"     Simple interrupted sutures",
"    </span>",
"    &nbsp;&mdash;&nbsp;If staples are not rapidly available, when brisk bleeding requires hemostasis by wound closure, or if the wound type or hair length make hair apposition difficult or impossible to perform, scalp lacerations may be closed with 3-0-or 4-0 nonabsorbable or absorbable (eg, coated polyglactin 910 [Vicryl Rapide&reg;]) simple, interrupted sutures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/23\">",
"     23",
"    </a>",
"    ]. When compared to nonabsorbable sutures, closure with Vicryl Rapide&reg; has added convenience, in that the patients do not need to return for suture removal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link&amp;anchor=H20#H20\">",
"     \"Closure of skin wounds with sutures\", section on 'Percutaneous skin closure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Galeal lacerations larger than approximately 0.5 cm should be approximated with 3.0 or 4.0 absorbable simple interrupted sutures (eg, Polyglactin 910 [Vicryl&reg;] and Poliglecaprone 25 [Monocryl&reg;]) regardless of the method of skin closure. Repair of a galeal laceration prevents subgaleal infections, spread of potential infections to the remainder of the scalp and underlying connective tissue, subgaleal hematoma, increased scarring, and other poor cosmetic outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30872/abstract/2\">",
"     2",
"    </a>",
"    ]. The galea is a key anchoring structure of the frontalis muscle. If the frontalis loses its anchoring point, contraction of that muscle can become asymmetric and noticeable to any observer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link&amp;anchor=H7#H7\">",
"     \"Closure of skin wounds with sutures\", section on 'Absorbable sutures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep scalp lacerations may also benefit from the placement of a pressure dressing for the first 24 hours to prevent hematoma formation (",
"    <a class=\"graphic graphic_figure graphicRef69739 \" href=\"mobipreview.htm?17/5/17490\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200685\">",
"    <span class=\"h1\">",
"     OTHER CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200693\">",
"    <span class=\"h2\">",
"     Tetanus prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus prophylaxis should be provided for all scalp wounds as indicated (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"     table 5",
"    </a>",
"    ). &nbsp;Pregnant women should receive immunization with tetanus and diphtheria toxoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=see_link&amp;anchor=H17#H17\">",
"     \"Immunizations during pregnancy\", section on 'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200700\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most scalp wounds do",
"    <strong>",
"     not",
"    </strong>",
"    warrant empiric antibiotic treatment. Prophylactic antibiotics may decrease the risk of wound infection in patients with animal or human bites or those with excessive wound contamination, vascular insufficiency (eg, peripheral artery disease), or immunodeficiency.",
"   </p>",
"   <p>",
"    Recommendations for the use of prophylactic antibiotics after the closure of skin wounds other than bite wounds are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link&amp;anchor=H38#H38\">",
"     \"Closure of skin wounds with sutures\", section on 'Prophylactic antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications and empiric oral antibiotic regiments for patients with animal bites (",
"    <a class=\"graphic graphic_table graphicRef75020 \" href=\"mobipreview.htm?37/4/37964\">",
"     table 1",
"    </a>",
"    ) and human bites (",
"    <a class=\"graphic graphic_table graphicRef69328 \" href=\"mobipreview.htm?6/17/6429\">",
"     table 2",
"    </a>",
"    ) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial management of animal and human bites\", section on 'Antibiotic prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2937436\">",
"    <span class=\"h2\">",
"     Bite wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bites, scratches, abrasions, or contact with animal saliva via mucous membranes or a break in the skin all can transmit rabies. Early wound cleansing is an important prophylactic measure, in addition to timely administration of rabies immune globulin and vaccine (",
"    <a class=\"graphic graphic_table graphicRef70600 \" href=\"mobipreview.htm?27/43/28347\">",
"     table 6",
"    </a>",
"    ). Indications for rabies prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=see_link&amp;anchor=H19#H19\">",
"     \"Rabies immune globulin and vaccine\", section on 'Dosing schedules and routes of administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=see_link&amp;anchor=H8#H8\">",
"     \"When to use rabies prophylaxis\", section on 'Types of exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any unvaccinated patient or individual negative for anti-HBs antibodies who is bitten by an individual positive for HBsAg should receive both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    (HBIG) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59736 \" href=\"mobipreview.htm?20/39/21116\">",
"     table 7",
"    </a>",
"    ). In addition, although the risk for transmitting HIV through saliva is extremely low, infection is of concern if there is blood in the saliva. Counseling regarding post-exposure HIV prophylaxis is appropriate in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial management of animal and human bites\", section on 'Viral prophylaxis after human bites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200748\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp wounds should be left open to air unless they require a pressure dressing (",
"    <a class=\"graphic graphic_figure graphicRef69739 \" href=\"mobipreview.htm?17/5/17490\">",
"     figure 4",
"    </a>",
"    ) to prevent hematoma formation. After 24 to 48 hours, wounds closed with staples or nonabsorbable sutures can be left open to air and cleansed gently with soap and water. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link&amp;anchor=H37#H37\">",
"     \"Closure of skin wounds with sutures\", section on 'Dressing and bathing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link&amp;anchor=H10#H10\">",
"     \"Closure of minor skin wounds with staples\", section on 'Wound care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Staples or nonabsorbable sutures should be removed after 7 to14 days. Small, superficial wounds with few staples or sutures are good candidates for staple or suture removal at seven days. Larger or deeper wounds warrant removal of staples or sutures at 10 to 14 days.",
"   </p>",
"   <p>",
"    Most clean scalp wounds do not need to be seen by a physician until suture removal, unless signs of infection develop. Highly contaminated wounds should be seen for follow-up in 48 to 72 hours. It is imperative that all patients or caregivers receive discharge instructions regarding the signs of wound infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education topics are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest in the UpToDate search box.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/51/6962?source=see_link\">",
"       \"Patient information: Stitches (The Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4200866\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with scalp lacerations require careful evaluation to determine the presence of life-threatening injuries; historical features that increase the risk of serious injury and complications after wound repair; and wound characteristics including extent, degree of contamination, presence of foreign bodies, and visible or palpable bony defects. (See",
"      <a class=\"local\" href=\"#H4198638\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding may be profuse and substantial blood loss can occur with scalp lacerations. Direct pressure for approximately 15 minutes with or without local injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      with epinephrine can often provide sufficient hemostasis. If these methods fail, the edges of the scalp wound can be everted manually or using hemostats or skin hooks and the wound rapidly closed with simple, interrupted sutures. In this situation, sutures provide circumferential wound closure and thus better control of bleeding than noncircumferential wound closure with staples. (See",
"      <a class=\"local\" href=\"#H4199182\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary closure (wound repair at initial presentation) is usually the preferred treatment for scalp lacerations through the dermis. Wounds with obvious signs of inflammation (redness, warmth, swelling, pus drainage) should not be closed primarily. (See",
"      <a class=\"local\" href=\"#H4199108\">",
"       'Indications for primary closure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4199115\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Local anesthesia typically provides adequate analgesia for the management of simple scalp lacerations in children and adults. (See",
"      <a class=\"local\" href=\"#H4199182\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Wound irrigation should be performed with normal saline or tap water (if the local water supply is sanitary) for most clean wounds. The volume of irrigation is based upon the wound size and degree of contamination. Hair trimming is often necessary to appreciate the extent of the scalp wound and to determine if full thickness skin lacerations are present. Hair shaving should be avoided as it may increase debris in the wound. Hair can also be patted down with petrolatum, water, or povidone-iodine ointment to allow for visualization of the wound. (See",
"      <a class=\"local\" href=\"#H4199182\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The equipment and techniques for closure of scalp lacerations are provided. (See",
"      <a class=\"local\" href=\"#H4199657\">",
"       'Equipment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4199680\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that scalp lacerations through the dermis undergo skin closure with surgical staples rather than sutures (",
"      <a class=\"graphic graphic_figure graphicRef69979 \" href=\"mobipreview.htm?6/5/6226\">",
"       figure 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although outcomes from either method are similar, staples are much more quickly placed. Sutures are an acceptable option if surgical staples are not available in a timely manner and are preferred over staples to provide hemostasis for brisk bleeding. (See",
"      <a class=\"local\" href=\"#H4199768\">",
"       'Surgical staples'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modified hair apposition (",
"      <a class=\"graphic graphic_figure graphicRef63626 \" href=\"mobipreview.htm?25/50/26403\">",
"       figure 3",
"      </a>",
"      ) is another technique that may be used instead of staples or sutures to close scalp lacerations. This approach is appropriate for wounds that are straight and less than 10 cm. Patients need to have hair that is longer than 1 cm and scalp bleeding must be controlled prior to the procedure. (See",
"      <a class=\"local\" href=\"#H4199775\">",
"       'Modified hair apposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Galeal lacerations larger than approximately 0.5 cm should be approximated with 3.0 or 4.0 absorbable simple interrupted sutures (eg, Polyglactin 910 [Vicryl&reg;] and Poliglecaprone 25 [Monocryl&reg;]) prior to skin closure, regardless of the method used. (See",
"      <a class=\"local\" href=\"#H4199768\">",
"       'Surgical staples'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4199775\">",
"       'Modified hair apposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should receive tetanus prophylaxis, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 5",
"      </a>",
"      ). Most scalp wounds do",
"      <strong>",
"       not",
"      </strong>",
"      warrant empiric antibiotic treatment. (See",
"      <a class=\"local\" href=\"#H4200685\">",
"       'Other considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scalp wounds should be left open to air unless they require a pressure dressing (",
"      <a class=\"graphic graphic_figure graphicRef69739 \" href=\"mobipreview.htm?17/5/17490\">",
"       figure 4",
"      </a>",
"      ) to prevent hematoma formation. After 24 to 48 hours, wounds closed with staples or nonabsorbable sutures can be left open to air and cleansed gently with soap and water. Staples or nonabsorbable sutures should be removed after 7 to 14 days. (See",
"      <a class=\"local\" href=\"#H4200748\">",
"       'Aftercare'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91529168\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/1\">",
"      Lee RH, Gamble WB, Robertson B, Manson PN. The MCFONTZL classification system for soft-tissue injuries to the face. Plast Reconstr Surg 1999; 103:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/2\">",
"      Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/3\">",
"      Saigal K, Winokur RS, Finden S, et al. Use of three-dimensional computerized tomography reconstruction in complex facial trauma. Facial Plast Surg 2005; 21:214.",
"     </a>",
"    </li>",
"    <li>",
"     Lammers RL. Methods of wound closure. In: Clinical Procedures in Emergency Medicine, 5th edition, Roberts JR, Hedges JR.  (Eds), Saunders Elsevier, Philadelphia 2010. p.592.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/5\">",
"      Wu G, Calamel PM, Shedd DP. THe hazards of injecting local anesthetic solutions with epinephrine into flaps: experimental study. Plast Reconstr Surg 1978; 62:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/6\">",
"      Reinisch J, Myers B. The effect of local anesthesia with epinephrine on skin flap survival. Plast Reconstr Surg 1974; 54:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/7\">",
"      Atabey A, Galdino G, El-Shahat A, Ramirez OM. The effects of tumescent solutions containing lidocaine and epinephrine on skin flap survival in rats. Ann Plast Surg 2004; 53:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/8\">",
"      Howell JM, Morgan JA. Scalp laceration repair without prior hair removal. Am J Emerg Med 1988; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/9\">",
"      Bennett RG. Selection of wound closure materials. J Am Acad Dermatol 1988; 18:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/10\">",
"      Edlich RF, Becker DG, Thacker JG, Rodeheaver GT. Scientific basis for selecting staple and tape skin closures. Clin Plast Surg 1990; 17:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/11\">",
"      Ritchie AJ, Rocke LG. Staples versus sutures in the closure of scalp wounds: a prospective, double-blind, randomized trial. Injury 1989; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/12\">",
"      Kanegaye JT, Vance CW, Chan L, Schonfeld N. Comparison of skin stapling devices and standard sutures for pediatric scalp lacerations: a randomized study of cost and time benefits. J Pediatr 1997; 130:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/13\">",
"      Brickman KR, Lambert RW. Evaluation of skin stapling for wound closure in the emergency department. Ann Emerg Med 1989; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/14\">",
"      Orlinsky M, Goldberg RM, Chan L, et al. Cost analysis of stapling versus suturing for skin closure. Am J Emerg Med 1995; 13:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/15\">",
"      MacGregor FB, McCombe AW, King PM, Macleod DA. Skin stapling of wounds in the accident department. Injury 1989; 20:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/16\">",
"      Khan AN, Dayan PS, Miller S, et al. Cosmetic outcome of scalp wound closure with staples in the pediatric emergency department: a prospective, randomized trial. Pediatr Emerg Care 2002; 18:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/17\">",
"      Stillman RM, Marino CA, Seligman SJ. Skin staples in potentially contaminated wounds. Arch Surg 1984; 119:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/18\">",
"      Johnson A, Rodeheaver GT, Durand LS, et al. Automatic disposable stapling devices for wound closure. Ann Emerg Med 1981; 10:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/19\">",
"      Edlich RF, Gubler K, Stevens HS, et al. Scientific basis for the selection of surgical staples and tissue adhesives for closure of skin wounds. J Environ Pathol Toxicol Oncol 2010; 29:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/20\">",
"      Hock MO, Ooi SB, Saw SM, Lim SH. A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study). Ann Emerg Med 2002; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/21\">",
"      Ong ME, Chan YH, Teo J, et al. Hair apposition technique for scalp laceration repair: a randomized controlled trial comparing physicians and nurses (HAT 2 study). Am J Emerg Med 2008; 26:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/22\">",
"      Karaduman S, Y&uuml;r&uuml;kt&uuml;men A, G&uuml;ryay SM, et al. Modified hair apposition technique as the primary closure method for scalp lacerations. Am J Emerg Med 2009; 27:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30872/abstract/23\">",
"      Aderriotis D, S&agrave;ndor GK. Outcomes of irradiated polyglactin 910 Vicryl Rapide fast-absorbing suture in oral and scalp wounds. J Can Dent Assoc 1999; 65:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16696 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30872=[""].join("\n");
var outline_f30_9_30872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4200866\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4201456\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4198638\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4198712\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4198847\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4198993\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4199042\">",
"      INDICATIONS FOR SUBSPECIALTY CONSULTATION OR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4199100\">",
"      WOUND REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199108\">",
"      Indications for primary closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199115\">",
"      Contraindications and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199182\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199657\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4199680\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199768\">",
"      Surgical staples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4199775\">",
"      Modified hair apposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4200180\">",
"      Simple interrupted sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4200685\">",
"      OTHER CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4200693\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4200700\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2937436\">",
"      Bite wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4200748\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4200866\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91529168\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16696\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16696|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/5/6226\" title=\"figure 2\">",
"      Skin stapling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/50/26403\" title=\"figure 3\">",
"      Modified hair apposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/5/17490\" title=\"figure 4\">",
"      Scalp pressure dressing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16696|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/58/42918\" title=\"picture 1\">",
"      Scalp laceration through the galea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16696|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/4/37964\" title=\"table 1\">",
"      Empiric oral antibiotics animal bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/17/6429\" title=\"table 2\">",
"      Oral antibiotics human bites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/56/26509\" title=\"table 3\">",
"      Comparison of commonly infiltrated local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/33/5662\" title=\"table 4\">",
"      Suture selection for facial and scalp lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 5\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/43/28347\" title=\"table 6\">",
"      Rabies postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/39/21116\" title=\"table 7\">",
"      Postexposure prophylaxis hepatitis B vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/62/34792?source=related_link\">",
"      Allergic reactions to local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/53/12122?source=related_link\">",
"      Assessment and management of facial lacerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20377?source=related_link\">",
"      Initial management of animal and human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/51/6962?source=related_link\">",
"      Patient information: Stitches (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34618?source=related_link\">",
"      Procedural sedation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/25/3481?source=related_link\">",
"      Skull fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/24/13704?source=related_link\">",
"      Skull fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20088?source=related_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_9_30873="Lateral canthal rhytides";
var content_f30_9_30873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59956%7EDERM%2F54110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59956%7EDERM%2F54110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Lateral canthal rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple wrinkles are present lateral to the eye (left). The wrinkles are more prominent during smiling (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection sites for lateral canthal rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examples of sites for botulinum toxin injection of the orbicularis oculi muscle for the treatment of lateral canthal rhytides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30873=[""].join("\n");
var outline_f30_9_30873=null;
var title_f30_9_30874="Molecular biology of prostate cancer";
var content_f30_9_30874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular biology of prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Donald Vander Griend, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/9/30874/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/9/30874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/1\">",
"     1",
"    </a>",
"    ]. If completely localized within the capsule of the gland, prostate cancer can be cured by definitive local therapy such as radical prostatectomy or radiation therapy. In contrast, non-organ confined disease is most often fatal, and therapy is mainly palliative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic prostate cancers are lethal because they are heterogeneously composed of both androgen-dependent and androgen-independent malignant cells. For those cells that are androgen-dependent, a critical level of androgen is required to activate a sufficient number of androgen receptors (ARs) so that transcription of death-signaling genes is repressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/2\">",
"     2",
"    </a>",
"    ]. Androgen ablation therapies allow these genes to be expressed, triggering the biochemical cascade that results in apoptotic cell death, resulting in the eradication of the large fraction of androgen-dependent cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In contrast, androgen ablation does not induce apoptosis in androgen-independent cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/5\">",
"     5",
"    </a>",
"    ]; their eventual outgrowth is responsible for the lethality of advanced disease. The median survival duration in men with castrate-resistant prostate cancer is approximately one year, and it is unclear whether survival is meaningfully prolonged by any therapeutic regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although prostate cancer typically presents in men over the age of 65, a growing body of evidence suggests that prostatic carcinogenesis is initiated much earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/6\">",
"     6",
"    </a>",
"    ]. Prostatic intraepithelial neoplasia (PIN) is thought to represent a precursor of adenocarcinoma, although not all cases progress to invasive disease. One of the most pressing clinical problems presented by prostate cancer is the difficulty in predicting its clinical course based upon clinical or histologic features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26937?source=see_link\">",
"     \"Precancerous lesions of the prostate: Pathology and clinical implications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prostate cancer progression has been related to a number of genetic abnormalities that affect the androgen receptor (AR) and other molecules that are involved in the regulation of cell survival and apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/7\">",
"     7",
"    </a>",
"    ]. In a manner similar to that described for colorectal tumorigenesis, a multistep process of prostate carcinogenesis has been proposed, in which progressive accumulation of genetic alterations is postulated to facilitate cellular transformation from normal prostate epithelium to PIN, invasive neoplasia, and the state of androgen independence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the last decade, a number of genes involved in or associated with prostate cancer have been identified and characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/7\">",
"     7",
"    </a>",
"    ]. Many of these genes or their protein products are under study for their value in clinical staging (sometimes termed \"molecular staging\") with the goal of more closely tailoring the selection of treatment to expected prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/9\">",
"     9",
"    </a>",
"    ]. Perhaps more importantly, mechanistic studies to determine the biochemical result of specific molecular changes might reveal additional targets for therapy. Unfortunately, the heterogeneity of prostate cancers, the variability in analytic techniques, and the lack of suitable model systems for different stages of in prostate progression have hampered progress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Here we will provide an overview of the molecular changes that are proposed to be involved in the initiation and progression of prostate cancer, particularly those that accompany metastatic disease and androgen independence. The diagnosis, staging, and treatment of prostate cancer are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHROMOSOMAL ABERRATIONS AND CANDIDATE GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques such as fluorescence in situ hybridization (FISH), comparative genomic hybridization, and microsatellite analysis have demonstrated losses or gains in various chromosomes that are associated with prostate cancer progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In many instances, the target gene or genes have been identified. Further advances in positional cloning technology and the information provided by the human genome project are expected to facilitate the identification of candidate genes within these chromosomal regions.",
"   </p>",
"   <p>",
"    There are three categories of chromosomal changes that may play a role in the development and progression of prostate cancer: those that are associated with genetic predisposition (eg, 1q deletions); somatic alterations that result in amplification of presumed oncogenes (eg, 7p, and 8q); and somatic alterations that result in the loss of function of presumed tumor suppressor genes (eg, 8p, 10q, 12q, 13q, and 17p). Genetic factors that may influence prostate cancer risk are discussed elsewhere. Here, we will provide an overview of selected molecular changes that occur during prostate cancer development and progression, with a particular emphasis on their prognostic and therapeutic value. Specific details of these chromosomal alterations are beyond the scope of this review and are discussed more in depth elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Oncogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oncogenes are homologs of normal cellular genes in which a mutational change results in constitutive activation and gain of function. These mutations either accelerate cellular growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proliferation (eg, c-myc, beta catenin, HER2, Ras) or facilitate abnormal cell division (eg, MKP-1, Bcl 2, telomerase).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     c-myc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gain of chromosome 8q sequences is a common feature of prostate cancer, particularly metastatic tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/16\">",
"     16",
"    </a>",
"    ]. The target gene is not known, but one candidate is c-myc, which is amplified in a subset of advanced tumors. The myc oncogene, located at chromosome 8q24, encodes a nuclear protein that is involved in the control of normal cell growth, differentiation, and apoptosis. Increasing levels of overexpression correlate with advancing stage and grade of prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], and high levels of amplification are found in a subset of men with androgen-independent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     MKP-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several oncogenes involved in prostate carcinogenesis activate mitogen-activated protein (MAP) kinases, which can relay both proliferative (via extracellular regulated kinases [ERK]) and apoptotic signals (via jun N-terminal protein kinases [JNK]) to the nucleus. MAP kinase phosphatase (MKP)-1 is a dual-specificity MAP kinase phosphatase that dephosphorylates both phosphotyrosine and phosphothreonine residues on the JNK, and ERK MAP kinases, providing overall protection from apoptotic influences. Overexpression of MKP-1 has been detected in the earliest stages of prostate cancer, including PIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one report of 51 prostate cancers, MKP-1 was overexpressed in PIN lesions, but its expression decreased with higher histologic grade and advanced disease stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Bcl-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of the B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (bcl-2) oncogene by prostate cancers confers resistance to apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/25\">",
"     25",
"    </a>",
"    ], and upregulation of bcl-2 (particularly in conjunction with p53 mutations, see below) is a frequent and important step in the progression to advanced or hormone independent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Bcl-2 tends to be expressed more strongly as malignant change progresses along the continuum from preinvasive to metastatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. As a result, the bcl-2 protein is a potential target for clinical intervention, particularly using antisense molecules such as oblimersen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Its value as a prognostic marker is less certain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Telomerase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telomeres are specialized nucleoprotein structures that cap the ends of linear eukaryotic chromosomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/41\">",
"     41",
"    </a>",
"    ]. Because of incomplete DNA replication at the ends of chromosomes, telomeres progressively shorten with each cell division in eukaryotic cells. This progressive loss of telomeres is postulated to be the \"clock\" by which normal cells senesce with age, and telomere maintenance appears to be an important regulator of cellular life span.",
"   </p>",
"   <p>",
"    Telomerase, a ribonucleoprotein enzyme, compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. In normal somatic cells, telomerase activity is usually undetectable, with the exception of hematopoietic cells, hair follicles, intestinal crypt cells, and epidermal basal cells. In contrast, upregulation of telomerase and amplification of telomeric DNA is detected in many cancers, including up to 90 percent of prostate cancers, and in high-grade PIN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/42-48\">",
"     42-48",
"    </a>",
"    ]. Higher grade cancers appear to have maximally elevated telomerase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Telomerase has been exploited both as a diagnostic tool and a therapeutic strategy in prostate cancer. A urinary assay for telomerase has been proposed as a noninvasive means of detecting prostate cancer, while the therapeutic potential of agents targeting telomerase and telomere-associated enzymes is beginning to be explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Beta catenin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catenin family of proteins is thought to play a critical role in cell-cell adhesion. However, the role of beta catenin (b-catenin) in prostate tumorigenesis appears to be distinct from cell adhesion. Although most cases of prostate cancer show downregulation of beta catenin at the mRNA and protein level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], approximately 5 percent contain activating mutations within the b-catenin gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This gain of function mutations results in protein stabilization and accumulation in the nucleus, where b-catenin forms a transcriptional complex that is capable of upregulating target genes, such as the AR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Up to 20 percent of lethal prostate cancers contain nuclear b-catenin, suggesting a more common role in advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ras pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ras oncogene is thought to be important in the pathogenesis in many human malignancies (eg, non small cell lung cancer).",
"   </p>",
"   <p>",
"    In prostate cancer, Ras amplification does not seem to play a major role in disease initiation and development in American men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], although somewhat higher mutation rates are reported in Japanese men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, epigenetic inactivation of the Ras association domain family 1A gene (RASSF1A, located on chromosome 3p21), via promoter methylation is present in approximately 60 to 70 percent of prostate cancers, particularly more aggressive tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative mechanism for prostate cancer pathogenesis involves the DAB2IP gene, which encodes a protein that is a negative regulator of the RAS signal transduction pathway. A polymorphism of DAB2IP was associated with aggressive prostate cancer in an exploratory genome-wide association study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein product of the HER2 oncogene (also known as c-erbB-2) is a receptor tyrosine kinase belonging to the epidermal growth factor receptor family. Its role in prostate tumorigenesis is controversial. HER2 protein overexpression is detected in 20 to 25 percent of hormone-naive primary tumors and in 60 to 78 percent of cancers following androgen ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, the biologic significance of this finding is unclear. With the exception of one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/66\">",
"     66",
"    </a>",
"    ], high-level amplification of the gene, representing the predominant mechanism of HER2 pathway activation (at least in breast cancer), is not observed in prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/20,64,65,67,68\">",
"     20,64,65,67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     EGFR pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermal growth factor receptor (EGFR), also known as HER-1 or c-erbB-1, belongs to a family of receptors that includes the HER2 protein (c-erbB-2), as well as HER-3, and HER-4. EGFR is a transmembrane glycoprotein whose intracellular domain includes a tyrosine kinase, which is a therapeutic target in a number of other malignancies.",
"   </p>",
"   <p>",
"    A possible role for EGFR in prostate cancer pathogenesis was suggested by a study of 2497 prostate cancers for whom follow-up data was available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/69\">",
"     69",
"    </a>",
"    ]. Overall, EGFR was expressed in 18 percent of cases. EGFR expression was associated with higher grade tumors, more advanced stage, and a decrease in recurrence free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fatty acid synthase",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common occurrence in many cancers is the increased synthesis of long-chain fatty acids. Fatty acid synthase (FASN) is a key enzyme in this process. In prostate cancers, FASN expression is thought to function as an oncogene by preventing apoptosis. This is documented by the increased cell proliferation and tumorigenic growth of FASN-expressing prostate cell lines and transgenic models, as well as in human prostate specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20797464\">",
"    <span class=\"h3\">",
"     HOXB13",
"    </span>",
"    &nbsp;&mdash;&nbsp;The homeobox B13 (HOXB13) gene codes for a transcription factor that is important in prostate development. Sequencing studies have identified the G84E variant as associated with hereditary prostate cancer in some families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/71\">",
"     71",
"    </a>",
"    ]. The mechanism by which HOXB13 acts is not yet understood, but an understanding of this pathway may provide additional insights into sporadic cases of prostate cancer as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors for prostate cancer\", section on 'Genome-wide association studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Oncogenes as a result of a gene fusion event",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recurrent gene fusion as a result of a chromosomal rearrangement has been identified in prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/72\">",
"     72",
"    </a>",
"    ]. Fusion of the androgen-regulated gene TMPRSS2 and the ETS transcription family members (ERG, ETV1, ETV4, and ETV5) has been described as one of the most common recurrent genomic alterations in prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/73\">",
"     73",
"    </a>",
"    ]. Such TMPRSS2-ERG fusion products are found in nearly one half of PSA-screened prostate cancer patients and are absent in biopsies from benign lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Furthermore, TMPRSS2-ERG fusions show a high correlation with disease recurrence after surgery for localized prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/77\">",
"     77",
"    </a>",
"    ]. Since this initial observation, other permutations of gene fusions have been found, all of which involve an ETS transcription family member fused to a number of partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to oncogenes, tumor suppressor genes exert their influence by removing inhibition to control of cell growth so that normal control mechanisms are no longer operative. As examples, the wild type forms of genes such as GSTP1 protect cells from DNA damage, and the p53 gene product prevents cells from proliferating after damage has occurred; mutations in these putative tumor suppressor genes result in loss of these functions.",
"   </p>",
"   <p>",
"    Deactivation of tumor suppressor genes can result from chromosomal deletion, loss of expression due to promoter hypermethylation, specific genetic mutations that result in deletion of a specific gene, or point mutations that result in the production of an aberrant protein product with reduced function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     PTEN/MMAC 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protein product of the PTEN (phosphatase and tensin homologue, also termed MMAC1) gene, located on chromosome 10q, negatively regulates the phosphoinositide 3-kinase",
"    <span class=\"nowrap\">",
"     (PI3-kinase)/Akt",
"    </span>",
"    pathway. This pathway plays a critical role in a variety of growth factor signaling pathways that control the cell cycle and apoptosis. Although germline mutations of MMAC1 are found in numerous cancer predisposition syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/78\">",
"     78",
"    </a>",
"    ], mutations in the PTEN gene have not been found in men with hereditary prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, PTEN clearly plays an important role in the progression of prostate cancer. PTEN alterations appear to be a late event, possibly influencing metastatic potential and progression to androgen independence rather than tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. As examples, high rates of loss of heterozygosity (LOH) for 10q are reported in advanced prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], and PTEN mutations are more commonly found in metastatic compared to localized prostate cancers (30 to 58 versus 5 to 27 percent of cases, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/80,83-89\">",
"     80,83-89",
"    </a>",
"    ]. A role for PTEN mutations in resistance to chemotherapy is also proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/90\">",
"     90",
"    </a>",
"    ], and gene therapy approaches using transfected wild type PTEN are being developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mxi1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The product of the Mxi1 gene on chromosome 10q, is a member of the helix-loop-helix-leucine zipper family and a potential negative regulator of c-myc (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Oncogenes'",
"    </a>",
"    above). These proteins seem to be essential in cellular growth control",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induction and maintenance of the differentiated state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/92\">",
"     92",
"    </a>",
"    ]. In prostate cancers, loss of Mxi1 expression, rather than point mutation, is the primary means of inactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/81,93-95\">",
"     81,93-95",
"    </a>",
"    ]. Mice lacking the Mix1 protein are susceptible to tumorigenesis, and Mxi1-deficient prostate epithelial cells have increased proliferative activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/92\">",
"     92",
"    </a>",
"    ]. Others, using subtraction hybridization, have identified Mix-1 as one of eight target genes that are differentially expressed in androgen-dependent and androgen-independent prostate cancer xenografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     GSTP1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermethylation of the p-class glutathione S-transferase gene promoter is possibly the most common genetic event in prostate cancer and appears to be an early event in tumorigenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/96\">",
"     96",
"    </a>",
"    ]. Glutathione S-transferases (GSTPs) are a family of enzymes that participate in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione; this protects the cells from environmental carcinogenic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/97\">",
"     97",
"    </a>",
"    ]. Over 90 percent of prostate carcinomas and 70 percent of high grade PIN lesions have lost GSTP1 expression due to hypermethylation of the 5'-CpG island [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/98,99\">",
"     98,99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     p53",
"    </span>",
"    &nbsp;&mdash;&nbsp;The p53 gene, located at chromosome 17p13.1, encodes a nuclear protein that acts as a transcription factor, blocking the progression of cells through the cell cycle late in the G1 phase. The p53 gene plays a central role in the regulation of transcriptional events in the cell nucleus, particularly in the response to DNA damaging agents, such as ionizing radiation and a variety of other carcinogens. The ability of wild type p53 to prevent the proliferation of damaged cells has led to its description as the \"guardian of the genome\". A mutation in the p53 gene abrogates the G1 checkpoint and changes the cellular response to DNA damage, thus promoting genetic instability and the acquisition of additional mutations.",
"   </p>",
"   <p>",
"    The significance of p53 mutations in prostate cancer is controversial. A number of studies using different analytical tools yield widely varying mutation rates among human prostate cancer specimens, a situation that is complicated by significant intratumoral heterogeneity within a single specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/100\">",
"     100",
"    </a>",
"    ]. Mutations in p53 have been reported in 60 to 90 percent of advanced prostate cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/101\">",
"     101",
"    </a>",
"    ], as well as between 10 to 20 percent of primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/102-106\">",
"     102-106",
"    </a>",
"    ]. The reported incidence in PIN lesions ranges from 6 to 56 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/106,107\">",
"     106,107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these methodologic difficulties, accumulating data support a prognostic role for p53 mutations in human prostate cancer. The presence of p53 mutations in radical prostatectomy specimens is associated with increased proliferative rates, higher grade disease, androgen independence, and a poor clinical outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/18,26,30,37,40,102,103,108-116\">",
"     18,26,30,37,40,102,103,108-116",
"    </a>",
"    ]. Furthermore, it has been proposed that p53 mutations in primary tumors are associated with increased metastatic potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/40,101,102,117\">",
"     40,101,102,117",
"    </a>",
"    ]. In addition, abnormal p53 expression has been associated with higher rates of biochemical progression in men managed with radiation therapy and androgen deprivation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/118\">",
"     118",
"    </a>",
"    ]. In a recent study, there was a positive correlation between the expression of the proliferation marker Ki-67, p53, and the p53 regulator MDM2 and the development of distant metastases and overall mortality from prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, studies of p53 assessment in prostate needle biopsies have provided conflicting results, likely due to sampling variability, tumor heterogeneity, and multifocality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/38,39,120,121\">",
"     38,39,120,121",
"    </a>",
"    ]. A prospective multicenter study is needed to confirm the value of p53 assessment in needle biopsy prior to radical prostatectomy.",
"   </p>",
"   <p>",
"    Although human trials have not begun, preclinical results suggest a potential therapeutic benefit for gene therapy using viral constructs that contain wild type p53 in men with prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     TGF-b1",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal prostate epithelial cells, transforming growth factor beta (TGF-b) induces apoptosis and inhibits proliferation. However, prostate tumors frequently do not express TGF-b receptors (type I and II), and as they progress, tumor cells shift to autocrine regulation of TGF-b. TGF-b overexpression coupled with the underexpression of TGF-b receptors allows prostate cancers to escape the growth inhibitory effect of TGF-b.",
"   </p>",
"   <p>",
"    In prostate cancers, abnormalities in TGF-b are associated with higher histologic grade, a more malignant phenotype, and greater metastatic potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/124-128\">",
"     124-128",
"    </a>",
"    ]. As an example, in one report of men undergoing prostatectomy for apparently localized disease, elevated preoperative plasma levels of TGF-b were a strong predictor of biochemical progression, presumably the result of occult metastatic disease at the time of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/129\">",
"     129",
"    </a>",
"    ]. Preoperative levels of TGF-b have been incorporated into a nomogram to predict biochemical progression-free survival following radical prostatectomy, although measurement of preoperative levels is not routine in most centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rb/p16 pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome 13q is one of the most frequently altered chromosomes in prostate cancer. In one study, 58 percent of primary tumors showed LOH for 13q, and allelic loss was even more frequent in metastatic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/131\">",
"     131",
"    </a>",
"    ]. Two known tumor suppressor genes (retinoblastoma [Rb] and BRCA2) map to this region, although other putative tumor suppressor genes may also reside in this location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Rb gene, so named because deletions or mutations of this gene are critical in the pathogenesis of retinoblastoma, is also involved in the pathogenesis of a variety of other solid tumors. The Rb gene encodes for a nuclear protein (pRb1) that is an important regulator of the cell cycle during",
"    <span class=\"nowrap\">",
"     G0/G1",
"    </span>",
"    phase; its activity is dependent upon its phosphorylation status during the cell cycle. At the end of mitosis and during most of",
"    <span class=\"nowrap\">",
"     G0/G1,",
"    </span>",
"    pRb1 is dephosphorylated, which actively suppresses the transition from G1 to S phase. Phosphorylation of pRb1 by cyclin-dependent kinases (CDKs) in late G1 phase leads to its inactivation, thereby leading to cell cycle progression. Multiple CDK inhibitors have been identified (eg, p16INK4A [also called CDKN2A or MTS-1, on chromosome 9p] and",
"    <span class=\"nowrap\">",
"     p21WAF1/CIP1)",
"    </span>",
"    which block entry into S phase by decreasing pRb1 phosphorylation. This entire pathway of cell cycle control is often referred to as the",
"    <span class=\"nowrap\">",
"     Rb/p16",
"    </span>",
"    pathway.",
"   </p>",
"   <p>",
"    In many solid tumors, dysregulation of the",
"    <span class=\"nowrap\">",
"     Rb/p16",
"    </span>",
"    pathway is an early event in tumorigenesis. However, the role of this pathway in prostate cancer is unclear. In early prostate cancer, deletion of p16 and Rb genes are reported in some but not all series, and the role of these genetic alterations in tumorigenesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumor progression remains undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/133-141\">",
"     133-141",
"    </a>",
"    ]. Other studies suggest that mutations in the Rb gene and mutation or promoter methylation of the CDKN2A gene are more common in advanced prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/135,142-148\">",
"     135,142-148",
"    </a>",
"    ]. Preclinical gene therapy studies using adenoviral vectors containing wild type p16 or Rb genes are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/149,150\">",
"     149,150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although p21 is a growth inhibitory molecule, most series report expression in 25 to 30 percent of primary prostate tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/151-154\">",
"     151-154",
"    </a>",
"    ]. Furthermore, overexpression appears to be associated with progression toward androgen-independent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/151\">",
"     151",
"    </a>",
"    ]. In vitro studies of antisense strategies directed against p21 show early promise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     CDKI1B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cyclin dependent kinase inhibitor 1B gene (CDKI1B, previously called",
"    <span class=\"nowrap\">",
"     p27/Kip1)",
"    </span>",
"    maps to 12p12-13.1, a region that is frequently deleted in advanced prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/156\">",
"     156",
"    </a>",
"    ]. CDKI1B is an inhibitor of CDK4; as such it is a negative regulator of cell cycle initiation. In regards to prostate cancer, several clinical studies have indicated a loss of CDKI1B protein expression in prostate cancers and PIN, indicating this as a potentially early event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/157-160\">",
"     157-160",
"    </a>",
"    ]. Furthermore, loss of CDKI1B protein expression in radical prostatectomy specimens has been shown to be an adverse prognostic factor in patients with clinically localized prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/144,158,161-164\">",
"     144,158,161-164",
"    </a>",
"    ] and in those undergoing salvage prostatectomy after radiation therapy failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/165\">",
"     165",
"    </a>",
"    ]. Because of this, loss of CDKI1B has been suggested as a component of molecular staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/163,166\">",
"     163,166",
"    </a>",
"    ]. As with other putative tumor suppressor genes, preclinical studies with recombinant adenovirus expressing CDKI1B are underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/167\">",
"     167",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nkx3.1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nkx3.1 is an androgen-regulated prostate-specific homeobox gene on chromosome 8q that appears to be critical in the development of the normal prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/168,169\">",
"     168,169",
"    </a>",
"    ]. In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/170-172\">",
"     170-172",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/169,173\">",
"     169,173",
"    </a>",
"    ], decreased expression of Nkx3.1 is associated with both PIN and invasive prostate cancer. Others have shown a correlation between abnormalities in Nkx3.1 expression and advanced grade and hormone independent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/172-174\">",
"     172-174",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     KLF6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kruppel-like factor 6 (KLF6) is a zinc finger transcription factor. Its possible role as a tumor suppressor gene in prostate cancer was suggested in one series in which LOH for this allele was shown in 17 of 22 primary prostate tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/175\">",
"     175",
"    </a>",
"    ]. Further study of this gene and its role in prostate cancer is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Metastasis suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced prostate carcinoma is characterized by local invasion, spread to regional lymph nodes, and more distant osseous metastases. Much effort has been directed toward the identification and characterization of genes that are involved in metastatic behavior, both for the purpose of obtaining prognostic indicators for aggressive disease, and to understand why and how prostate cancer preferentially metastasizes to bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=see_link&amp;anchor=H2#H2\">",
"     \"Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The identification of several genes that appear to function as metastasis suppressor genes has provided important insight into factors regulating metastatic spread and growth. By definition, metastasis suppressor genes specifically prevent the formation of overt metastasis without affecting the formation or growth of primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/176,177\">",
"     176,177",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique of microcell-mediated chromosomal transfer (MMCT) has been the most commonly used method to identify putative metastasis suppressor genes in prostate cancer. It is based upon the work of Ichikawa et al, who demonstrated that fusion of nonmetastatic and highly metastatic Dunning rat prostate carcinoma cells produced nonmetastatic hybrid cells which were unaffected in terms of tumorigenicity and in vitro growth rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/178\">",
"     178",
"    </a>",
"    ]. Subsequent studies suggested that the loss of specific chromosomes was responsible for the metastatic phenotype. MMCT was then used to selectively introduce single tagged human chromosomes into metastatic recipient cells, thereby permitting the localization of metastasis suppressor genes to specific human chromosomes. Two of the genes identified in the rat Dunning model (KAI1 and CD44) appear to suppress metastatic potential at an early stage of the metastatic cascade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     KAI-1/CD82",
"    </span>",
"    &nbsp;&mdash;&nbsp;KAI1 was the first prostate cancer metastasis suppressor gene identified using MMCT; it maps to chromosome 11p11.2 and downregulation of this gene has been found in advanced prostate tumors and metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/179,180\">",
"     179,180",
"    </a>",
"    ]. The KAI1 gene encodes a membrane glycoprotein that is widely expressed, but its precise biochemical function in metastasis suppression has not been clearly defined. In vitro studies suggest that it may play a role in integrin signaling, cell adhesion, and motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/181-183\">",
"     181-183",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     MKK4 (17p11.2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metastasis suppressor gene MKK4 (Mitogen activated protein kinase Kinase 4, also known as JNKK1 or SEK1) was identified in MMCT studies introducing human chromosome 17 into metastatic Dunning AT6.1 rat prostate cancer cells, and assaying for metastasis suppression in SCID mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/184\">",
"     184",
"    </a>",
"    ]. MKK4 functions as an activator of both the JNK and p38 stress-activated protein kinases (SAPKs), and in mice it suppresses metastatic colonization, the final step of the metastatic cascade in which disseminated cancer cells grow into lethal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/185\">",
"     185",
"    </a>",
"    ]. In clinical specimens, loss of MKK4 protein correlates with increasing tumor grade, and there is a loss of MKK4-mediated metastasis suppression in advanced tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     E-cadherin (16q22)",
"    </span>",
"    &nbsp;&mdash;&nbsp;E-cadherin (CDH1) is a Ca2+-dependent homotypic cell adhesion molecule that is implicated as a",
"    <span class=\"nowrap\">",
"     tumor/invasion",
"    </span>",
"    suppressor in human carcinomas; it also functions as a binding partner for beta catenin, which is overexpressed in advanced prostate cancers (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Oncogenes'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Aberrant E-cadherin expression appears to be associated with high histologic grade and more aggressive tumor behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/187-190\">",
"     187-190",
"    </a>",
"    ], and deletions of chromosome 16q",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of E-cadherin function are common in prostate cancer metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/191,192\">",
"     191,192",
"    </a>",
"    ]. Furthermore, using MMCT, 16q has been strongly associated with suppression of metastatic ability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/193\">",
"     193",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence supporting the role of E-cadherin as a prognostic marker comes from the observation that decreased expression of E-cadherin and increased expression of N-cadherin is associated with adverse clinicopathologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     CD44 (11p13)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell adhesion molecules such as CD44 are uniformly expressed in normal prostate cells; in high grade prostate epithelial neoplasia (PIN), staining is reduced and erratic, while in invasive cancers, expression ceases. CD44 suppresses the metastatic potential of Dunning AT3.1 rat prostate cancer cells in the MMTC assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/185\">",
"     185",
"    </a>",
"    ], and decreased expression of certain CD44 isoforms correlates with higher tumor grade, aneuploidy, and the presence of distant metastases in patients with prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/195-201\">",
"     195-201",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ACQUIRED ANDROGEN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of men have a favorable initial response to androgen ablation, the development of hormone resistance is inevitable and thought responsible for the lethality of advanced prostate cancer. Multiple mechanisms have been postulated to account for the acquisition of androgen independence. A detailed review of the specific molecular changes that are associated with androgen-independence is beyond the scope of this discussion, although these changes are well reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/15,201\">",
"     15,201",
"    </a>",
"    ]. Here we will provide a brief overview of some of the mechanisms that are thought to underlie the development of androgen independence.",
"   </p>",
"   <p>",
"    In view of the importance of androgens to the growth of prostate cancer, it is reasonable to ask if alterations in the AR could be responsible for androgen-independent growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/202\">",
"     202",
"    </a>",
"    ]. The AR gene is overexpressed in approximately 20 to 30 percent of HRPCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/203,204\">",
"     203,204",
"    </a>",
"    ], although more sensitive techniques such as gene expression profiling suggest that amplification is nearly universal when hormone-resistant human prostate cancer cell lines are compared to the hormone sensitive tumors from which they were derived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/205\">",
"     205",
"    </a>",
"    ]. In theory, such alterations might possibly enhance the response of the cancer cell to low levels of endogenous androgens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/206,207\">",
"     206,207",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activating mutations in the AR gene have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/208-210\">",
"     208-210",
"    </a>",
"    ]. Such mutations in the steroid binding domain may alter ligand specificity, allowing other nonandrogenic steroids as well as antiandrogens to bind and activate the mutant AR, even when the level of systemic androgen is fully suppressed. Androgen receptor mutations have been most intensely studied in the context of the antiandrogen withdrawal response, in which acquired mutations in the AR are thought to result in a paradoxical stimulatory effect of antiandrogens on prostate tumor cells. Mutations in the hormone binding domain of the AR have been detected in a small fraction of bone marrow specimens of men with castrate-resistant prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/209-211\">",
"     209-211",
"    </a>",
"    ]. In functional studies, these mutant receptors were stimulated rather than inhibited by some but not all antiandrogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/212\">",
"     212",
"    </a>",
"    ]. However, other data suggest that AR mutations are not responsible for the antiandrogen withdrawal response, and this remains a controversial area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/210\">",
"     210",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38520?source=see_link&amp;anchor=H6#H6\">",
"     \"Secondary endocrine therapies for castration resistant prostate cancer\", section on 'Antiandrogen withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other specific AR mutations may provide pathways for androgen escape in prostate cancer cells. As an example, a double mutation in the ligand binding domain of the AR was identified in a patient who failed androgen ablation, in which the binding affinity for androgens was decreased but that for glucocorticoids was enhanced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/213\">",
"     213",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another mechanism for androgen independent growth involves molecular changes in several regulatory genes that may prevent the transcription or expression of death signaling genes after androgen ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/214,215\">",
"     214,215",
"    </a>",
"    ], or prevent the cancer cells from responding to these apoptotic influences through constitutive expression of genes that are located downstream in the apoptotic cascade (eg, upregulation of bcl 2, see above). Alternatively, resistance to androgen ablation might also involve \"crosstalk\" between the AR and other signaling pathways that are induced by peptide growth factors. In theory, androgen-independent AR activation could then be achieved via other pathways that are activated by specific peptide growth factor receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/216,217\">",
"     216,217",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, molecular changes within the prostate cancer cells may result in the ability to synthesize and secrete specific ligands and their receptors, essentially creating an autocrine survival pathway that is independent of androgen signaling pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/218\">",
"     218",
"    </a>",
"    ]. One such example is the secretion of neurotrophin ligands and their trk receptors by hormone-resistant prostate cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/219\">",
"     219",
"    </a>",
"    ]. Small molecule inhibitors of these tyrosine kinase receptors can induce apoptosis in hormone-resistant prostate cancer cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/9/30874/abstract/220,221\">",
"     220,221",
"    </a>",
"    ], and these trk inhibitors are currently in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer continues to be a major health problem despite significant advances in prevention and early detection. The mechanistic characterization of genes shown to play a functional role in the development and progression of prostate cancer are beginning to provide important insights into the nature and behavior of the disease. The goal of these studies is to identify additional targets for staging and treatment.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/2\">",
"      Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/3\">",
"      Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50:3748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/4\">",
"      Gao J, Isaacs JT. Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. Cancer Res 1998; 58:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/5\">",
"      Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/6\">",
"      Miller DC, Hafez KS, Stewart A, et al. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/7\">",
"      Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170:2444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/8\">",
"      Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/9\">",
"      Moul, JW, et al. Molecular markers in prostate cancer. Clin Prostate Cancer 2002; 1:42.167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/10\">",
"      Alers JC, Rochat J, Krijtenburg PJ, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000; 80:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/11\">",
"      Wolter H, Trijic D, Gottfried HW, Mattfeldt T. Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol 2002; 41:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/12\">",
"      Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 1999; 35:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/13\">",
"      Karan D, Schmied BM, Dave BJ, et al. Decreased androgen-responsive growth of human prostate cancer is associated with increased genetic alterations. Clin Cancer Res 2001; 7:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/14\">",
"      Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000; 20:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/15\">",
"      Elo JP, Visakorpi T. Molecular genetics of prostate cancer. Ann Med 2001; 33:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/16\">",
"      Sato K, Qian J, Slezak JM, et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 1999; 91:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/17\">",
"      Buttyan R, Sawczuk IS, Benson MC, et al. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 1987; 11:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/18\">",
"      Qian J, Hirasawa K, Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/19\">",
"      Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/20\">",
"      Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999; 59:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/21\">",
"      Karan D, Kelly DL, Rizzino A, et al. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 2002; 23:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/22\">",
"      Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998; 153:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/23\">",
"      Magi-Galluzzi C, Mishra R, Fiorentino M, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997; 76:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/24\">",
"      Magi-Galluzzi C, Montironi R, Cangi MG, et al. Mitogen-activated protein kinases and apoptosis in PIN. Virchows Arch 1998; 432:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/25\">",
"      Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003; 8:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/26\">",
"      Apakama I, Robinson MC, Walter NM, et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/27\">",
"      Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/28\">",
"      Furuya Y, Krajewski S, Epstein JI, et al. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/29\">",
"      McDonnell TJ, Navone NM, Troncoso P, et al. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 1997; 157:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/30\">",
"      Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/31\">",
"      Stattin P, Damber JE, Karlberg L, et al. Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival. Urol Res 1996; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/32\">",
"      Baltaci S, Orhan D, Ozer G, et al. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int 2000; 85:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/33\">",
"      Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/34\">",
"      Gleave ME, Zellweger T, Chi K, et al. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002; 20:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/35\">",
"      Vilenchik M, Raffo AJ, Benimetskaya L, et al. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002; 62:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/36\">",
"      Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/37\">",
"      Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/38\">",
"      Stackhouse GB, Sesterhenn IA, Bauer JJ, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/39\">",
"      Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/40\">",
"      Concato J, Jain D, Uchio E, et al. Molecular markers and death from prostate cancer. Ann Intern Med 2009; 150:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/41\">",
"      Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003; 21:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/42\">",
"      Kageyama Y, Kamata S, Yonese J, Oshima H. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol 1997; 4:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/43\">",
"      Koeneman KS, Pan CX, Jin JK, et al. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998; 160:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/44\">",
"      Ozen M, Imam SA, Datar RH, et al. Telomeric DNA: marker for human prostate cancer development? Prostate 1998; 36:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/45\">",
"      Paradis V, Darg&egrave;re D, Laurendeau I, et al. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue. J Pathol 1999; 189:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/46\">",
"      Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998; 58:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/47\">",
"      Iczkowski KA, Pantazis CG, McGregor DH, et al. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma. Cancer 2002; 95:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/48\">",
"      Wang Z, Ramin SA, Tsai C, et al. Telomerase activity in prostate sextant needle cores from radical prostatectomy specimens. Urol Oncol 2001; 6:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/49\">",
"      Bearss DJ, Hurley LH, Von Hoff DD. Telomere maintenance mechanisms as a target for drug development. Oncogene 2000; 19:6632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/50\">",
"      Wang J, Krill D, Torbenson M, et al. Expression of cadherins and catenins in paired tumor and non-neoplastic primary prostate cultures and corresponding prostatectomy specimens. Urol Res 2000; 28:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/51\">",
"      Kallakury BV, Sheehan CE, Ross JS. Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol 2001; 32:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/52\">",
"      Chesire DR, Ewing CM, Sauvageot J, et al. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000; 45:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/53\">",
"      Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58:2520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/54\">",
"      Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60:4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/55\">",
"      Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/56\">",
"      Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 1991; 51:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/57\">",
"      Carter BS, Epstein JI, Isaacs WB. ras gene mutations in human prostate cancer. Cancer Res 1990; 50:6830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/58\">",
"      Shiraishi T, Muneyuki T, Fukutome K, et al. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res 1998; 18:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/59\">",
"      Konishi N, Hiasa Y, Tsuzuki T, et al. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997; 30:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/60\">",
"      Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002; 21:6835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/61\">",
"      Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62:3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/62\">",
"      Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/63\">",
"      Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/64\">",
"      Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001; 7:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/65\">",
"      Signoretti S, Montironi R, Manola J, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/66\">",
"      Kallakury BV, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/67\">",
"      Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer 1997; 79:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/68\">",
"      Mark HF, Feldman D, Das S, et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/69\">",
"      Schlomm T, Kirstein P, Iwers L, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007; 13:6579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/70\">",
"      Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009; 101:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/71\">",
"      Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/72\">",
"      Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/73\">",
"      Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/74\">",
"      Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/75\">",
"      Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006; 66:8337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/76\">",
"      Mosquera JM, Mehra R, Regan MM, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15:4706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/77\">",
"      Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/78\">",
"      Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/79\">",
"      Latini JM, Rieger-Christ KM, Wang DS, et al. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions. J Urol 2001; 166:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/80\">",
"      Whang YE, Wu X, Suzuki H, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 1998; 95:5246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/81\">",
"      Gray IC, Phillips SM, Lee SJ, et al. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995; 55:4800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/82\">",
"      Rubin MA, Gerstein A, Reid K, et al. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000; 31:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/83\">",
"      Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57:4997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/84\">",
"      Dong JT, Sipe TW, Hyytinen ER, et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 1998; 17:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/85\">",
"      Feilotter HE, Nagai MA, Boag AH, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/86\">",
"      Pesche S, Latil A, Muzeau F, et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998; 16:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/87\">",
"      Suzuki H, Freije D, Nusskern DR, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/88\">",
"      Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998; 4:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/89\">",
"      Vlietstra RJ, van Alewijk DC, Hermans KG, et al. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/90\">",
"      Huang H, Cheville JC, Pan Y, et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276:38830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/91\">",
"      Davies MA, Kim SJ, Parikh NU, et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002; 8:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/92\">",
"      Schreiber-Agus N, Meng Y, Hoang T, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998; 393:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/93\">",
"      Eagle LR, Yin X, Brothman AR, et al. Mutation of the MXI1 gene in prostate cancer. Nat Genet 1995; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/94\">",
"      Prochownik EV, Eagle Grove L, Deubler D, et al. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/95\">",
"      Kawamata N, Park D, Wilczynski S, et al. Point mutations of the Mxil gene are rare in prostate cancers. Prostate 1996; 29:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/96\">",
"      Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994; 91:11733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/97\">",
"      Mannervik B, Alin P, Guthenberg C, et al. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A 1985; 82:7202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/98\">",
"      Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 1997; 6:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/99\">",
"      Brooks JD, Weinstein M, Lin X, et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1998; 7:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/100\">",
"      Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/101\">",
"      Meyers FJ, Gumerlock PH, Chi SG, et al. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/102\">",
"      Navone NM, Labate ME, Troncoso P, et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 1999; 161:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/103\">",
"      Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994; 151:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/104\">",
"      Al-Maghrabi J, Vorobyova L, Chapman W, et al. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens. Mod Pathol 2001; 14:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/105\">",
"      Downing SR, Jackson P, Russell PJ. Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. Urol Oncol 2001; 6:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/106\">",
"      Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998; 11:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/107\">",
"      Myers RB, Oelschlager D, Srivastava S, Grizzle WE. Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994; 25:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/108\">",
"      Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/109\">",
"      Visakorpi T, Kallioniemi OP, Heikkinen A, et al. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/110\">",
"      Fan K, Dao DD, Schutz M, Fink LM. Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma. Diagn Mol Pathol 1994; 3:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/111\">",
"      Macera MJ, Godec CJ, Sharma N, Verma RS. Loss of heterozygosity of the TP53 tumor suppressor gene and detection of point mutations by the non-isotopic RNAse cleavage assay in prostate cancer. Cancer Genet Cytogenet 1999; 108:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/112\">",
"      Effert PJ, McCoy RH, Walther PJ, Liu ET. p53 gene alterations in human prostate carcinoma. J Urol 1993; 150:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/113\">",
"      Aprikian AG, Sarkis AS, Fair WR, et al. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/114\">",
"      Kallakury BV, Figge J, Ross JS, et al. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. Hum Pathol 1994; 25:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/115\">",
"      Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001; 48:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/116\">",
"      Quinn DI, Henshall SM, Head DR, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000; 60:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/117\">",
"      Stapleton AM, Timme TL, Gousse AE, et al. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res 1997; 3:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/118\">",
"      D'Amico AV, Halabi S, Vollmer R, et al. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology 2008; 71:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/119\">",
"      Khor LY, Bae K, Paulus R, et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 2009; 27:3177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/120\">",
"      Ruijter E, van de Kaa C, Aalders T, et al. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group. Mod Pathol 1998; 11:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/121\">",
"      Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/122\">",
"      Eastham JA, Grafton W, Martin CM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000; 164:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/123\">",
"      Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002; 13:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/124\">",
"      Glynne-Jones E, Harper ME, Goddard L, et al. Transforming growth factor beta 1 expression in benign and malignant prostatic tumors. Prostate 1994; 25:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/125\">",
"      Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996; 2:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/126\">",
"      Wikstr&ouml;m P, Stattin P, Franck-Lissbrant I, et al. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998; 37:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/127\">",
"      Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000; 42:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/128\">",
"      Kim IY, Ahn HJ, Lang S, et al. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 1998; 4:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/129\">",
"      Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001; 19:2856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/130\">",
"      Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003; 21:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/131\">",
"      Hyytinen ER, Frierson HF Jr, Boyd JC, et al. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999; 25:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/132\">",
"      Fiedler U, Ehlers W, Meye A, et al. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. Anticancer Res 2001; 21:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/133\">",
"      Jarrard DF, Sarkar S, Shi Y, et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res 1999; 59:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/134\">",
"      Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A 1990; 87:7762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/135\">",
"      Li C, Larsson C, Futreal A, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/136\">",
"      Tricoli JV, Gumerlock PH, Yao JL, et al. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 1996; 15:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/137\">",
"      Chi SG, deVere White RW, Muenzer JT, Gumerlock PH. Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res 1997; 3:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/138\">",
"      Chakravarti A, DeSilvio M, Zhang M, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007; 25:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/139\">",
"      Gu K, Mes-Masson AM, Gauthier J, Saad F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog 1998; 21:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/140\">",
"      Mangold KA, Takahashi H, Brandigi C, et al. p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. J Urol 1997; 157:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/141\">",
"      Heidenreich B, Heidenreich A, Sesterhenn A, et al. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 2000; 38:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/142\">",
"      Jarrard DF, Modder J, Fadden P, et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 2002; 185:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/143\">",
"      Phillips SM, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/144\">",
"      Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/145\">",
"      Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/146\">",
"      Chen W, Weghorst CM, Sabourin CL, et al. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996; 17:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/147\">",
"      Kaltz-Wittmer C, Klenk U, Glaessgen A, et al. FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 2000; 80:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/148\">",
"      Sarkar FH, Sakr W, Li YW, et al. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 1992; 21:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/149\">",
"      Bookstein R, Shew JY, Chen PL, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/150\">",
"      Steiner MS, Zhang Y, Farooq F, et al. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 2000; 7:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/151\">",
"      Fizazi K, Martinez LA, Sikes CR, et al. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002; 8:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/152\">",
"      Sarkar FH, Li Y, Sakr WA, et al. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate 1999; 40:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/153\">",
"      Osman I, Drobnjak M, Fazzari M, et al. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999; 5:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/154\">",
"      Baretton GB, Klenk U, Diebold J, et al. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 1999; 80:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/155\">",
"      Martinez LA, Yang J, Vazquez ES, et al. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 2002; 23:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/156\">",
"      Kibel AS, Schutte M, Kern SE, et al. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 1998; 58:5652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/157\">",
"      Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997; 3:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/158\">",
"      Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998; 90:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/159\">",
"      Erdamar S, Yang G, Harper JW, et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999; 12:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/160\">",
"      Fern&aacute;ndez PL, Arce Y, Farr&eacute; X, et al. Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. J Pathol 1999; 187:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/161\">",
"      Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/162\">",
"      Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998; 90:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/163\">",
"      Vis AN, van Rhijn BW, Noordzij MA, et al. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/164\">",
"      Thomas GV, Schrage MI, Rosenfelt L, et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 2000; 164:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/165\">",
"      Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000; 6:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/166\">",
"      Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am 2001; 28:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/167\">",
"      Katner AL, Hoang QB, Gootam P, et al. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1). Prostate 2002; 53:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/168\">",
"      Schneider A, Brand T, Zweigerdt R, Arnold H. Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mech Dev 2000; 95:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/169\">",
"      Ornstein DK, Cinquanta M, Weiler S, et al. Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol 2001; 165:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/170\">",
"      Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002; 62:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/171\">",
"      Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002; 22:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/172\">",
"      Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60:6111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/173\">",
"      Xu LL, Srikantan V, Sesterhenn IA, et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol 2000; 163:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/174\">",
"      He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/175\">",
"      Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/176\">",
"      Jaeger EB, Samant RS, Rinker-Schaeffer CW. Metastasis suppression in prostate cancer. Cancer Metastasis Rev 2001; 20:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/177\">",
"      Kauffman EC, Robinson VL, Stadler WM, et al. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 2003; 169:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/178\">",
"      Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res 1991; 51:3788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/179\">",
"      Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/180\">",
"      Bouras T, Frauman AG. Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour grade. J Pathol 1999; 188:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/181\">",
"      Kawana Y, Komiya A, Ueda T, et al. Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer. Prostate 1997; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/182\">",
"      Dong JT, Suzuki H, Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56:4387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/183\">",
"      Ueda T, Ichikawa T, Tamaru J, et al. Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer. Am J Pathol 1996; 149:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/184\">",
"      Yoshida BA, Dubauskas Z, Chekmareva MA, et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999; 59:5483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/185\">",
"      Yoshida BA, Chekmareva MA, Wharam JF, et al. Prostate cancer metastasis-suppressor genes: a current perspective. In Vivo 1998; 12:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/186\">",
"      Kim HL, Vander Griend DJ, Yang X, et al. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 2001; 61:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/187\">",
"      Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54:3929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/188\">",
"      Otto T, Rembrink K, Goepel M, et al. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res 1993; 21:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/189\">",
"      Richmond PJ, Karayiannakis AJ, Nagafuchi A, et al. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997; 57:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/190\">",
"      Graff JR, Herman JG, Lapidus RG, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55:5195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/191\">",
"      Pan Y, Matsuyama H, Wang N, et al. Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer. Prostate 1998; 36:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/192\">",
"      Latil A, Cussenot O, Fournier G, et al. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 1997; 57:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/193\">",
"      Mashimo T, Watabe M, Cuthbert AP, et al. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998; 58:4572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/194\">",
"      Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13:7003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/195\">",
"      Lou W, Krill D, Dhir R, et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999; 59:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/196\">",
"      Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/197\">",
"      Noordzij MA, van Steenbrugge GJ, Schr&ouml;der FH, Van der Kwast TH. Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer 1999; 84:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/198\">",
"      Noordzij MA, van Steenbrugge GJ, Verkaik NS, et al. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997; 3:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/199\">",
"      Nagabhushan M, Pretlow TG, Guo YJ, et al. Altered expression of CD44 in human prostate cancer during progression. Am J Clin Pathol 1996; 106:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/200\">",
"      G&uuml;nthert U, Stauder R, Mayer B, et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/201\">",
"      Cude KJ, Dixon SC, Guo Y, et al. The androgen receptor: genetic considerations in the development and treatment of prostate cancer. J Mol Med (Berl) 1999; 77:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/202\">",
"      Culig Z, Klocker H, Bartsch G, et al. Androgen receptors in prostate cancer. J Urol 2003; 170:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/203\">",
"      Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/204\">",
"      Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/205\">",
"      Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/206\">",
"      Hyytinen ER, Haapala K, Thompson J, et al. Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest 2002; 82:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/207\">",
"      Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/208\">",
"      Wall&eacute;n MJ, Linja M, Kaartinen K, et al. Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999; 189:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/209\">",
"      Suzuki H, Akakura K, Komiya A, et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996; 29:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/210\">",
"      Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/211\">",
"      Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/212\">",
"      Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/213\">",
"      Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/214\">",
"      Chang GT, Steenbeek M, Schippers E, et al. Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst 2000; 92:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/215\">",
"      July LV, Akbari M, Zellweger T, et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/216\">",
"      Abreu-Martin MT, Chari A, Palladino AA, et al. Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol 1999; 19:5143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/217\">",
"      Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/218\">",
"      Isaacs JT. Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 2000; 92:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/219\">",
"      Weeraratna AT, Dalrymple SL, Lamb JC, et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 2001; 7:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/220\">",
"      Dionne CA, Camoratto AM, Jani JP, et al. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998; 4:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/9/30874/abstract/221\">",
"      George DJ, Dionne CA, Jani J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59:2395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6926 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30874=[""].join("\n");
var outline_f30_9_30874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHROMOSOMAL ABERRATIONS AND CANDIDATE GENES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Oncogenes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - c-myc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - MKP-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Bcl-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Telomerase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Beta catenin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ras pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - HER2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - EGFR pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fatty acid synthase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20797464\">",
"      - HOXB13",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Oncogenes as a result of a gene fusion event",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - PTEN/MMAC 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mxi1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - GSTP1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - p53",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - TGF-b1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rb/p16 pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - CDKI1B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nkx3.1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - KLF6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Metastasis suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - KAI-1/CD82",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - MKK4 (17p11.2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - E-cadherin (16q22)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - CD44 (11p13)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ACQUIRED ANDROGEN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41622?source=related_link\">",
"      Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26937?source=related_link\">",
"      Precancerous lesions of the prostate: Pathology and clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38520?source=related_link\">",
"      Secondary endocrine therapies for castration resistant prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_9_30875="Gout diet PI";
var content_f30_9_30875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diet recommendations for gout",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       The current recommendations for lowering levels of urate in your blood include eating less:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Red meat",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Seafood",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Beer and hard alcohol (eg, gin, vodka)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Foods and drinks that contain high-fructose corn syrup (found in sweets and non-diet sodas)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       You are encouraged to eat and drink:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Low-fat dairy products",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Foods made with complex carbohydrates (whole grains, brown rice, oats, beans)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; A moderate amount of wine (up to two 5 ounce servings per day) is not likely to increase the risk of a gout attack",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Coffee may decrease the risk of gout attacks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Vitamin C (500 mg per day) has a mild urate-lowering effect and may be recommended",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Changes in diet are often recommended, along with medications. Making changes in your diet without taking a medicine is not likely to make a big difference in your blood urate levels; following a very strict gout diet only lowers blood urate levels slightly (15 to 20 percent).",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Dietary guidelines for patients with gout have changed over time, and it is not completely clear which combination of foods is best. The list above includes a few suggestions to lower your urate level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30875=[""].join("\n");
var outline_f30_9_30875=null;
var title_f30_9_30876="Acetaminophen preparations";
var content_f30_9_30876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common dosage forms of acetaminophen (paracetamol)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Strength",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples of US trade names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extended release caplet",
"       </td>",
"       <td>",
"        650 mg",
"       </td>",
"       <td>",
"        Tylenol Arthritis Pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extra strength tablets, capsules, caplets, gelcaps, geltabs",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        Genapap Extra Strength, Genebs Extra Strength, Tylenol Extra Strength, Medpap Extra Strength, Aspirin Free Anacin&reg; Maximum Strength, Cetafen Extra, Redutemp, Valorin Extra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Tablets",
"       </td>",
"       <td>",
"        325 mg",
"       </td>",
"       <td>",
"        Cetafen, Genapap, Genebs ,Tylenol, Valorin, Mapap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 mg",
"       </td>",
"       <td>",
"        Mapap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Chewable tablets",
"       </td>",
"       <td>",
"        80 mg",
"       </td>",
"       <td>",
"        Children's Genapap, Children's Mapap, Children's Tylenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 mg",
"       </td>",
"       <td>",
"        Junior Strength Tylenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Liquid, syrup, elixir, suspension",
"       </td>",
"       <td>",
"        160 mg/5 mL (32 mg/mL)",
"       </td>",
"       <td>",
"        Redutemp, Children's Genapap, Children's Silapap, Children's Mapap Children's Tylenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        500 mg/15 mL (33.3 mg/mL)",
"       </td>",
"       <td>",
"        Tylenol Sore Throat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drops*",
"       </td>",
"       <td>",
"        100 mg/mL (80 mg/0.8 mL)",
"       </td>",
"       <td>",
"        Infant Genapap, Infantaire, Infant's Silapap Liquiprin for Children, Infant's Mapap, Infant's Tylenol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suppositories",
"       </td>",
"       <td>",
"        80, 120, 325, 650 mg",
"       </td>",
"       <td>",
"        Acephen, Feverall, Mapap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravenous solution&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        10 mg/mL",
"       </td>",
"       <td>",
"        Ofirmev",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *As of 2011, in an effort to minimize pediatric dosing errors, the Consumer Healthcare Products Association, in conjunction with the US Federal Drug Administration, is phasing out formulations&nbsp;that contain 100 mg per ml (infant acetaminophen drops) so that pediatric liquid preparations obtained in the United States after that time will all contain a concentration of 32 mg/ml (160 mg per 5 mL). However, 100 mg per mL solutions are likely to continue to be given to children from infant acetaminophen drops preparations purchased by caregivers&nbsp;before this phase out.",
"     <br>",
"      <br>",
"       &bull;NOTE: Tenfold dosing errors&nbsp;and toxicity&nbsp;from intravenous acetaminophen have occurred in small children when the calculated dose in mg is INCORRECTLY administered as the volume in mL because the concentration of the&nbsp;solution is 10 mg/mL. In the United States, intravenous acetaminophen is not&nbsp;licensed for use in&nbsp;children under&nbsp;two years of age.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30876=[""].join("\n");
var outline_f30_9_30876=null;
var title_f30_9_30877="Digoxin and total mortality";
var content_f30_9_30877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digoxin has no effect on total mortality in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 6800 patients with symptomatic heart failure and a left ventricular ejection fraction &le;45 percent who were randomized to digoxin or placebo, there was no difference in total mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30877=[""].join("\n");
var outline_f30_9_30877=null;
var title_f30_9_30878="daEPOCH-R for non-Hodgkin lymphoma";
var content_f30_9_30878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F88411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F88411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R) for non-Hodgkin lymphoma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Rituximab",
"        </strong>",
"       </td>",
"       <td>",
"        375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in normal saline (NS) or 5 percent dextrose in water (D5W) to a final concentration of 1 to 4 mg/mL. Initial infusion: start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated",
"        <sup>",
"         [2]",
"        </sup>",
"        . In the absence of an initial infusion reaction, for subsequent infusions, administer 20 percent of the total dose over the first 30 minutes and the remaining 80 percent over 60 minutes, as tolerated. The 90-minute infusion schedule should NOT be used in patients who have clinically significant cardiovascular disease or have a circulating lymphocyte count &ge;5000/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 0 or 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etoposide",
"        </strong>",
"       </td>",
"       <td>",
"        50 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"       <td rowspan=\"3\">",
"        Dilute in a 24-hour supply of etoposide, doxorubicin, and vincristine in 500 mL NS and administer as continuous infusion over 24 hours per day through central venous line. Solution must be protected from light to maintain stability.",
"       </td>",
"       <td rowspan=\"3\">",
"        Days 1 to 4 (96 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        10 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vincristine",
"        </strong>",
"       </td>",
"       <td>",
"        0.4 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day IV (dose not capped)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        750 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in with 250 mL NS or D5W and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prednisone",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        per day orally",
"       </td>",
"       <td>",
"        Administer first dose 30 minutes prior to chemotherapy on day 1, then subsequent doses every 24 hours on days 2 to 5.",
"       </td>",
"       <td>",
"        Days 1 to 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Granulocyte colony-stimulating factor",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Start day 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with acetaminophen and diphenhydramine, with or without an H2 receptor blocker, 30 minutes prior to at least the first and second infusions of rituximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin and vincristine are vesicants; avoid extravasation. Etoposide is an irritant. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is an essential component of this regimen. Regular or pegylated granulocyte colony-stimulating factor may be used according to center policy. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial prophylaxis",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Adjustment of initial cyclophosphamide, doxorubicin, etoposide, and vincristine doses may be needed for preexisting liver dysfunction",
"        <sup>",
"         [3-6]",
"        </sup>",
"        . In addition, dose adjustment of etoposide and cyclophosphamide may be required for renal dysfunction. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatitis screening:",
"        </strong>",
"        Patients should be screened for hepatitis B and C prior to starting rituximab, and, if positive, considered for lamivudine prophylaxis. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac screening:",
"        </strong>",
"        Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiation of therapy. Dose alterations should be considered for LVEF &lt;50 percent, and doxorubicin therapy is contraindicated in patients with LVEF &lt;30 percent at initiation, those with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count twice weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative doxorubicin dose. Reassess LVEF periodically during daEPOCH-R therapy, as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Carriers of hepatitis B or C should be monitored for clinical and laboratory signs of active infection during and following completion of therapy. Rituximab should be discontinued if reactivation occurs. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelosuppression:",
"        </strong>",
"        Each new cycle should be delayed until ANC is &gt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . Doses of etoposide, doxorubicin, and cyclophosphamide are adjusted based upon the nadir ANC and platelet counts",
"        <sup>",
"         [1]",
"        </sup>",
"        :",
"        <br/>",
"        - If nadir ANC &ge;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , increase doses by 20 percent over preceding cycle.",
"        <br/>",
"        - If ANC &lt;500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        on one or two measurements, doses remain the same as preceding cycle.",
"        <br/>",
"        - If ANC &lt;500 on &ge;3 measurements or platelets &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on one measurement, doses reduced by 20 percent from preceding cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neuropathy:",
"        </strong>",
"        Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Wilson WH, et al. Blood 2002; 99:2685.",
"      </li>",
"      <li>",
"       Rituxan (rituximab for injection). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide for injection). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).",
"      </li>",
"      <li>",
"       Doxorubicin hydrochloride injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).",
"      </li>",
"      <li>",
"       Vincristine (vincristine sulfate for injection). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).",
"      </li>",
"      <li>",
"       Etoposide injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at: www.dailymed.nlm.nih.gov, accessed December 18, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30878=[""].join("\n");
var outline_f30_9_30878=null;
var title_f30_9_30879="C2 Hangman fracture lateral xray";
var content_f30_9_30879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C2 pedicle fractures: Hangman's fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Traumatic spondylolysis of C2 (so-called \"hangman's fracture\") is an unstable injury that occurs when the cervicocranium (the skull, atlas, and axis functioning as a unit) is thrown into extreme hyperextension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_9_30879=[""].join("\n");
var outline_f30_9_30879=null;
